使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Charles River Laboratories fourth quarter and full year 2025 earnings conference call. This call is being recorded.
女士們、先生們,感謝各位的耐心等待,歡迎參加查爾斯河實驗室2025年第四季及全年財報電話會議。本次通話正在錄音。
(Operator Instructions)
(操作說明)
I would now like to turn the conference over to your host, Todd Spencer, Vice President of Investor Relations. Please go ahead.
現在我將把會議交給主持人,投資者關係副總裁托德·斯賓塞。請繼續。
Todd Spencer - Corporate Vice President, Investor Relations
Todd Spencer - Corporate Vice President, Investor Relations
Good morning and welcome to Charles River Laboratory's fourth quarter in full year 2025 earnings and 2026 guidance conference call and webcast. This morning, I am joined by Jim Foster, Chair, President and Chief Executive Officer; Birgit Girshick, Executive Vice President and Chief Operating Officer; and Mike Knell, Senior Vice President, Interim Chief Financial Officer, and Chief Accounting Officer.
早安,歡迎參加查爾斯河實驗室2025年第四季及全年收益和2026年業績展望電話會議和網路直播。今天上午,與我一同出席的有:董事長、總裁兼首席執行官吉姆·福斯特;執行副總裁兼首席營運官比爾吉特·吉爾希克;以及高級副總裁、臨時首席財務官兼首席會計官邁克·克內爾。
They will comment on our results for the fourth quarter of 2025, as well as our financial guidance for 2026. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks which we posted on the investor relations section of our website at ir.criver.com.
他們將對我們 2025 年第四季的業績以及 2026 年的財務預期發表評論。演講結束後,他們將回答問題。我們已將與今天演講相關的幻燈片簡報發佈在公司網站 ir.criver.com 的投資者關係版塊中。
A webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on our investor relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans, and prospects for the company constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.
本次電話會議的網路直播回放將於今天會議結束後約兩小時開始提供,也可在我們的投資者關係網站上存取。會議回放將在下個季度的電話會議上提供。我想提醒你們,我們有一個安全的港灣。我們對公司未來預期、計畫和前景所作的所有評論均構成 1995 年《私人證券訴訟改革法案》規定的前瞻性陳述。
Actual results may differ materially from those indicated. During the call, we will primarily discuss non-GAAP financial measures which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP.
實際結果可能與所示結果有重大差異。在電話會議中,我們將主要討論非GAAP財務指標,我們認為這些指標有助於投資人更了解我們的核心經營績效和績效指引。非GAAP財務指標並非旨在被認為優於或取代依照GAAP編製的經營績效。
In accordance with regulation G, you can find the comparable GAAP measures and reconciliations on our Investor Relations section of our website. I will now turn the call over to Jim Foster.
根據 G 條例,您可以在我們網站的投資者關係部分找到可比較的 GAAP 指標和調整表。現在我將把電話轉給吉姆·福斯特。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
Thank you and good morning. As Todd mentioned, I'm pleased to be joined today by Birgit Girshick, who will become our next CEO when I retire in May, as well as our interim CFO, Mike Knell. Birgit will provide an overview of our 2026 guidance and the key drivers behind our outlook. But before I hand the call over to her, I will provide details on our fourth quarter and full year 2025 financial results. As well as an update on our latest developments and market trends.
謝謝,早安。正如托德所提到的,我很高興今天能與比爾吉特·吉爾希克(Birgit Girshick)以及我們的臨時首席財務官邁克·克內爾(Mike Knell)一起出席。比爾吉特·吉爾希克將在我五月退休後成為我們的下一任執行長。Birgit 將概述我們 2026 年的業績指引以及我們展望背後的關鍵驅動因素。但在我把電話交給她之前,我將詳細介紹我們 2025 年第四季和全年的財務表現。同時,我們也會介紹我們最新的發展動態和市場趨勢。
We were pleased that our 2025 financial results were at the upper ends of the revenue and non-GAAP earnings per share ranges that we provided in November. Beyond our financial results, the fourth quarter capped a year that was marked by the stabilization of the biopharma demand environment, including substantial improvements in DSA net bookings, particularly during the first and fourth quarters.
我們很高興地看到,我們 2025 年的財務表現達到了我們在 11 月份提供的收入和非 GAAP 每股收益範圍的上限。除了財務表現之外,第四季也為這一年畫上了句號,這一年的特點是生物製藥需求環境趨於穩定,包括DSA淨預訂量大幅改善,尤其是在第一季和第四季。
We also advanced several strategic initiatives, that will enable the company to better capitalize on future growth opportunities and renew our focus on scientific innovation that will reinforce our position as the leader in pre-clinical drug development.
我們也推動了幾項策略性舉措,這將使公司能夠更好地利用未來的成長機會,並重新聚焦科學創新,從而鞏固我們在臨床前藥物開發領域的領導地位。
At different points during 2025, demand from both global biopharmaceutical clients and small and mid-size biotechnology clients showed signs of improvement. Many of our global biopharma clients progressed through their restructuring and pipeline reprioritization activities.
在 2025 年的不同時期,全球生物製藥客戶和中小型生物技術客戶的需求都顯示出改善的跡象。我們許多全球生物製藥客戶都順利完成了重組和產品線重新排序活動。
And after holding back spending in 2024, moved their programs forward with more urgency when new budgets were released in early 2025, which led to strong DSA bookings at the start of last year. The biotech funding environment slowed in the first half of 2025, and we subsequently experienced softer demand trends from our small and mid-sized biotech clients during the summer months.
在 2024 年控制支出後,當 2025 年初發布新預算時,他們更加緊迫地推進了各項計劃,這導致去年年初 DSA 預訂量強勁增長。2025 年上半年生技融資環境放緩,隨後我們在夏季幾個月也經歷了中小生技客戶需求的疲軟趨勢。
However, with a reinvigorated funding environment in the second half of the year, including a record level of $28 billion in the fourth quarter, Biotech clients were the primary driver behind a steady sequential increase in the DSA netbook to bill in each month during the second half of the year.
然而,隨著下半年融資環境的復甦,包括第四季度創紀錄的 280 億美元,生物技術客戶成為下半年 DSA 淨帳簿每月穩定成長的主要驅動力。
As we disclosed at an investor conference last month, the DSA net book to bill improved to 1.1 times in the fourth quarter. Taking these factors into account, we are cautiously optimistic that the favorable DSA demand trends will continue in 2026 and result in a return to organic revenue growth in the second half of the year for both the DSA segment and the overall company.
正如我們上個月在投資者會議上披露的那樣,第四季度 DSA 淨帳面出貨率改善至 1.1 倍。考慮到這些因素,我們謹慎樂觀地認為,2026 年 DSA 的有利需求趨勢將持續,並將在下半年使 DSA 部門和整個公司恢復有機收入成長。
We have also made substantial progress on the strategic actions that we outlined in November to unlock long-term shareholder value, including strengthening and refining our portfolio, driving greater efficiency, and maintaining a balanced yet disciplined approach to capital deployment. To strengthen our portfolio, in January, we announced the planned acquisitions of the assets of KF Cambodia and PathoQuest.
我們在 11 月提出的釋放股東長期價值的策略行動方面也取得了實質進展,包括加強和完善我們的投資組合、提高效率以及保持平衡而又嚴謹的資本部署方式。為了加強我們的投資組合,我們在 1 月宣布了收購 KF Cambodia 和 PathoQuest 資產的計劃。
Both of these acquisitions are squarely aligned with our core competencies and are the result of lengthy successful partnerships. KF, the acquisition of which has already closed, has been our longtime NHP supplier in Cambodia and will further strengthen and secure our DSA supply chain. We expect it will generate meaningful operating margin improvement starting later this year through significant cost savings on NHP sourcing. Between KA and NovoPrim, we expect to own and internally source most of our future annual NHP supply requirements for the DSA segment.
這兩項收購都與我們的核心競爭力完全契合,也是長期成功合作的結果。KF 的收購已經完成,KF 一直是我們在柬埔寨的 NHP 供應商,此次收購將進一步加強和保障我們的 DSA 供應鏈。我們預計,從今年稍後開始,透過大幅節省天然健康產品採購成本,將帶來顯著的營業利潤率提升。我們希望透過 KA 和 NovoPrim 兩家公司,能夠擁有並內部採購未來 DSA 領域大部分年度 NHP 供應需求。
We continue to advance our NAM's capabilities with the planned acquisition of PathoQuest, which is expected to close within the next month. The company has been a partner of our biologics testing business since 2016 and provides an in vitro approach to manufacturing quality control testing for biologics. The CA and PathQuest acquisitions are excellent examples of capital deployment in core areas that will enhance our financial profile.
我們將繼續提升北美地區業務的能力,並計劃收購 PathoQuest,預計下個月完成。自 2016 年以來,該公司一直是我們的生物製品檢測業務合作夥伴,並為生物製品的生產品質控制檢測提供體外方法。CA 和 PathQuest 的收購是資本部署到核心領域的絕佳例子,這將提升我們的財務狀況。
And advance our scientific capabilities as we endeavor to capture a greater share of wallet from our clients. We will continue to evaluate additional M&A, including in the areas of bioanalysis and geographic expansion, in order to support our clients as they seek to drive greater efficiency and success in their drug development programs.
我們將持續提昇科學研究能力,並努力贏得客戶更大的市佔率。我們將繼續評估其他併購機會,包括生物分析和地理擴張領域,以支持我們的客戶在藥物開發專案中提高效率並取得成功。
We are also focused on continuing to build our NAM's portfolio or new approach methodologies in areas that are most relevant to clients and their scientific needs. We believe we have already established a solid foundation of NAM's capabilities, including our retrogenics Cell microarray platform for off-target screening and toxicity, our development of virtual control groups for safety assessment studies that utilize machine learning and other techniques. And most recently PathQuest's innovative next-gen sequencing platform.
我們也致力於持續建立 NAM 的產品組合或新的方法論,以滿足客戶及其科學需求。我們相信,我們已經為 NAM 的能力奠定了堅實的基礎,包括我們的用於脫靶篩選和毒性的逆轉錄細胞微陣列平台,以及我們利用機器學習和其他技術開發的用於安全性評估研究的虛擬對照組。最近,PathQuest 也推出了創新的下一代定序平台。
We are excited about current and future applications for NEMs and related innovations including AI. And we view these as enabling technologies to support the work that we do and is complementary to it. NAMs, including AI, has promised, but it still has challenges with data availability and proof of concept. So it will be a gradual, longer-term evolution led by science and the validation of new capabilities over time, particularly in a regulated safety assessment environment where patient safety is paramount.
我們對NEM的當前和未來應用以及包括人工智慧在內的相關創新感到興奮。我們認為這些技術是支持我們工作的賦能技術,並且是我們工作的補充。包括人工智慧在內的網路資產管理技術前景廣闊,但在數據可用性和概念驗證方面仍面臨挑戰。因此,這將是一個循序漸進、長期發展的進程,由科學引領,並隨著時間的推移不斷驗證新的能力,尤其是在受監管的安全評估環境中,病人安全至關重要。
Since we began to discuss NAMs in more detail last spring, there have not been any significant technological changes in drug development, and we have not experienced any notable changes in client behavior other than more frequent conversations about NAMs.
自從去年春天我們開始更詳細地討論新輔助療法以來,藥物研發方面沒有發生任何重大的技術變革,除了更頻繁地談論新輔助療法之外,我們也沒有經歷客戶行為的任何顯著變化。
We also continue to make progress on our plan to divest businesses totalling approximately 7% of 2025 annual revenue. These processes and negotiations with potential buyers are ongoing, and we continue to expect the planned divestitures will be completed by the middle of 2026.
我們也持續推動剝離業務的計劃,剝離業務總額將占到 2025 年年度收入的約 7%。與潛在買家的這些流程和談判仍在進行中,我們仍然預計計劃中的資產剝離將在 2026 年年中完成。
Assuming all transactions are completed, the expected non-GAAP earnings per share accretion of $0.30 on an annualized basis from the planned divestitures will be less for the partial year 2026 or closer to $0.10 per share because expected improvements in the operating performance of these businesses throughout the year.
假設所有交易都已完成,計劃剝離業務預計每年將帶來 0.30 美元的非 GAAP 每股收益增長,但由於預計這些業務在 2026 年全年的經營業績將有所改善,因此 2026 年部分年度的每股收益增長將減少至 0.10 美元左右。
Now I will recap our fourth quarter and full year consolidated performance. We reported revenue of $994.2 million in the fourth quarter of 2025, a complete 2.6% decline on an organic basis from the previous year, with revenue declines in all three business segments. For the full year, we reported revenue of $4.02 billion with an organic revenue decrease of 1.6% driven primarily by lower revenue in the DSA and manufacturing segments.
現在我將總結我們第四季和全年的綜合業績。我們公佈 2025 年第四季營收為 9.942 億美元,與去年同期相比,以自然成長計算下降了 2.6%,所有三個業務部門的營收均出現下降。全年來看,我們的營收為 40.2 億美元,有機營收下降 1.6%,主要原因是 DSA 和製造部門的營收下降。
By client segments, sales to both the global farm biopharma and small and mid-sized biotech client segments declined modestly for the full year. In the fourth quarter, sales to global biopharma clients rebounded meaningfully versus the prior year as these clients got back to work after pulling back on spending at the end of 2024.
按客戶群劃分,全年面向全球農業生物製藥客戶和中小型生物技術客戶群的銷售額均略有下降。第四季度,隨著全球生物製藥客戶在 2024 年底削減開支後恢復運營,其對全球生物製藥客戶的銷售額較上年同期出現了顯著反彈。
Sales to small and mid-sized biotech clients decreased modestly in the fourth quarter. Largely reflecting softer DSA bookings during the summer months. As a reminder, there's a natural lag between when DSA studies are booked and when they start and begin to generate revenue. Therefore, it will take one to two quarters to see the benefit of the stronger four quarter bookings.
第四季度,面向中小型生物技術客戶的銷售額略有下降。主要反映出夏季 DSA 預訂量較為疲軟。需要提醒的是,從 DSA 研究預約到研究開始並產生收入之間存在一定的時間差。因此,需要一到兩個季度才能看到強勁的四個季度預訂的好處。
The operating margin decreased 180 basis points year over year to 18.1% in the fourth quarter, principally driven by three anticipated factors lower revenue, higher staffing and NHP sourcing costs in the DSA segment, and the timing of NHP shipments in the RMS segment. For the full year, the operating margin declined by just 10 basis points to 19.8%.
第四季營業利潤率年減 180 個基點至 18.1%,主要受三個預期因素的影響:營收下降、DSA 部門人員配置和 NHP 採購成本增加,以及 RMS 部門 NHP 出貨時間。全年來看,營業利益率僅下降了 10 個基點,至 19.8%。
As the cost savings from restructuring and efficiency initiatives helped to protect the operating margin, which has been our stated goal. Earnings per share were $2.39 in the fourth quarter, a decrease of 10.2% from $2.66 in the fourth quarter of 2024.
重組和提高效率措施帶來的成本節約有助於保護營業利潤率,而這正是我們既定的目標。第四季每股收益為 2.39 美元,比 2024 年第四季的 2.66 美元下降了 10.2%。
In addition to the lower operating margin, the tax rate was also a meaningful year over year headwind in the fourth quarter. For 2025, earnings per share were nearly flat at $10.28 compared to $10.32 in 2024, as lower revenue was largely offset by the benefit of the cost saving initiative.
除了營業利潤率下降外,稅率也是第四季同比業績下滑的一個重要不利因素。2025 年每股收益與 2024 年的 10.32 美元基本持平,為 10.28 美元,原因是收入下降很大程度上被成本節約計劃帶來的好處所抵消。
Below the line items largely netted out with the higher tax rate in 2025 primarily offset by lower interest expense and a lower share count from stock repurchases earlier in the year. I will now provide additional details on the segment performance. DSA revenue in the fourth quarter was $591.6 million a decrease of 3.3% on an organic basis. The decline reflected lower study volume, particularly for discovery services, while DSA pricing and mix were relatively stable.
各項目之間的差額基本相抵,2025 年較高的稅率主要被較低的利息支出和年初股票回購導致的較少股份數量所抵消。接下來我將提供有關該細分市場表現的更多細節。DSA 第四季營收為 5.916 億美元,以有機成長計算下降了 3.3%。下降反映出研究量減少,尤其是發現服務,而DSA定價和組合相對穩定。
For the year, DSA revenue decreased 2.6% on an organic basis. As a result of client demand, we experienced a meaningful increase in revenue from NHP studies, resulting in an increase in the number of NHPs used in these studies in 2025, for which additional information can be found in the appendix of our slide presentation.
本年度,DSA 的營收以有機成長計算下降了 2.6%。由於客戶需求,我們從 NHP 研究中獲得的收入顯著增加,導致 2025 年這些研究中使用的 NHP 數量增加,有關更多資訊可在我們的幻燈片簡報的附錄中找到。
These trends reflect our clients' continued reliance on traditional in vivo methods to help ensure drug safety, even as we and our broader industry continue to evaluate applicable uses for NAMs and further expand our capabilities. We experienced a higher number of NHP study starts in the fourth quarter, and this trend is expected to continue into the first quarter.
這些趨勢反映出我們的客戶仍然依賴傳統的體內方法來幫助確保藥物安全,即便我們和我們所在的整個行業仍在繼續評估 NAM 的適用用途並進一步擴展我們的能力。第四季我們啟動的 NHP 研究數量較多,預計這一趨勢將持續到第一季。
As we mentioned in November, the higher than expected NHP steady demand led to increased NHP sourcing costs in the fourth quarter and will again in the first quarter. However, due in part to the acquisition of KF we expect NHP sourcing costs will normalize over the course of the year.
正如我們在 11 月所提到的,高於預期的 NHP 穩定需求導致第四季度 NHP 採購成本增加,第一季度也將再次增加。然而,部分原因是收購了 KF,我們預計 NHP 採購成本將在年內恢復正常。
As we previously disclosed, DSA demand KPIs improved in the fourth quarter, led by net book to bill of [1.12 times] on net bookings of $665 million representing a meaningful increase from 0.82 times in the third quarter.
正如我們之前披露的那樣,第四季度DSA需求KPI有所改善,淨訂單額與出貨額之比為1.12倍,淨訂單額為6.65億美元,較第三季度的0.82倍有了顯著增長。
The sequential improvement was principally driven by small and mid-sized biotech clients, while global biopharma clients also contributed with both sequential and year over year bookings increases. Proposal value continued to be stable to improve in the fourth quarter, as it was for most of the year, and cancellations remained at lower levels consistent with the third quarter.
環比成長主要由中小型生物技術客戶推動,而全球生物製藥客戶的訂單量較上季和年比均有所成長。第四季提案價值繼續保持穩定並有所提高,與今年大部分時間的情況相同,而取消數量則保持在與第三季度一致的較低水平。
At year end, the DSA backlog modestly improved to $1.86 billion from $1.80 billion at the end of the third quarter. Collectively, these trends lead us to believe that the favorable DSA demand environment will continue in 2026.
截至年底,DSA 積壓訂單略有改善,從第三季末的 18 億美元增至 18.6 億美元。總的來說,這些趨勢使我們相信,有利的DSA需求環境將在2026年持續維持。
However, it is important to note that this improvement may not be linear, as demonstrated in 2025, and also that fourth quarter and more recent bookings activity. Will not more fully benefit DSA revenue growth until the second quarter due to the normal lag between booking and study start.
然而,值得注意的是,這種改善可能並非線性發展,正如 2025 年所表明的那樣,第四季度及最近的預訂活動也表明了這一點。由於預訂和學習開始之間存在正常滯後,DSA 收入成長要到第二季才能得到更充分的促進。
The DSA operating margin was 20.1% in the fourth quarter, a 460 basis point decrease from the fourth quarter of 2024, and it was 24.2% for the full year representing a 150 basis point decline year over year. Both the fourth quarter and fully declines were driven by lower revenue and higher costs related to increased NHP sourcing costs. And study starts in the fourth quarter, as well as higher staffing costs as we had previously anticipated.
DSA 第四季的營業利潤率為 20.1%,比 2024 年第四季下降了 460 個基點;全年營業利潤率為 24.2%,年比下降了 150 個基點。第四季和全年下滑均由收入下降和與 NHP 採購成本增加相關的成本上升所致。研究將於第四季開始,同時人員配備成本也會像我們之前預期的那樣增加。
RMS revenue in the fourth quarter was $206.3 million a decrease of 0.9% on an organic basis for the year. RMS revenue increased 1.2% on an organic basis. The fourth quarter decline was primarily driven by two factors lower NHP revenue and lower sales volume from small models in North America. NHP revenue was impacted by the timing of certain shipments. Which, as previously noted, had been accelerated to earlier in the year.
RMS 第四季營收為 2.063 億美元,按全年有機成長計算下降了 0.9%。RMS收入以有機成長計算成長了1.2%。第四季下滑主要是由於兩個因素造成的:北美地區 NHP 收入下降和小型車型銷量下降。NHP 的收入受到某些貨物出貨時間的影響。如前所述,這項進程已提前至今年稍早進行。
In the small research models business, lower sales volume in North America reflected that in-house research activity by a large farmer and mid-sized biotech clients has not fully recovered. Revenue from academic and government accounts remained very stable, but the growth rate has slowed compared to prior year due in part to the government uncertainty, including the with NIH budgets. Small model pricing in North America and Europe continued to be a positive contributor to RMS revenue and in Europe is offsetting the expected volume declines.
在小型研究模型業務中,北美地區的銷售額下降反映出大型農場和中型生物技術客戶的內部研究活動尚未完全恢復。來自學術界和政府機構的收入保持非常穩定,但與前一年相比,成長速度有所放緩,部分原因是政府的不確定性,包括美國國立衛生研究院 (NIH) 的預算。北美和歐洲的小型車型定價繼續為 RMS 的收入做出積極貢獻,並且在歐洲抵消了預期的銷售下降。
In China, small model unit volume continued to grow nicely. Revenue from research model services increased in the fourth quarter, but occupancy for our cradle sites remained pressured by the early-stage biotech market environment.
在中國,小型車型銷售量持續保持良好成長勢頭。第四季研究模型服務收入有所成長,但由於早期生物技術市場環境的影響,我們孵化基地的入住率仍面臨壓力。
The RMS operating margin decreased by 90 basis points year over year to 21.9% in the fourth quarter, but increased by 110 basis points to 24.8% for the full year. The fourth quarter margin was primarily impacted by lower revenue for small models in North America and an unfavorable revenue mix due to the timing of NHP shipments. For the year, the operating margin improvement was primarily due to a favorable mix related to higher NHP revenue, as well as cost savings related to our restructuring initiatives.
第四季 RMS 的營業利潤率年減 90 個基點至 21.9%,但全年營業利潤率年增 110 個基點至 24.8%。第四季利潤率主要受到北美小型機型收入下降以及由於 NHP 出貨時間導致的收入結構不利的影響。本年度營業利潤率的提高主要歸功於 NHP 收入增加帶來的有利產品組合,以及重組計劃帶來的成本節約。
Manufacturing solutions revenue was $196.4 million for the fourth quarter, a decrease of 2.1% on an organic basis, and fully revenue declined 1.6% organically. The lower fourth quarter and full-year growth rates were primarily driven by lower CDMO revenue, principally the result of the loss of one commercial cell therapy client whose revenue declined by nearly $25 million in 2025.
第四季製造解決方案收入為 1.964 億美元,以有機成長計算下降了 2.1%,總收入以有機成長計算下降了 1.6%。第四季和全年成長率下降主要是由於 CDMO 收入下降,這主要是由於失去了商業細胞療法客戶,該客戶的收入在 2025 年下降了近 2500 萬美元。
The microbial solutions had a strong year with growth across all three testing platforms, EndoSafe, Celsis, and Accugenix. However, year-end client ordering patterns were not quite as robust as last year. Which caused the fourth quarter growth rate to slow.
微生物解決方案在過去一年表現強勁,在 EndoSafe、Celsis 和 Accugenix 這三個測試平台上均實現了成長。然而,年底的客戶訂單模式並不像去年那麼強勁。這導致第四季成長放緩。
We were pleased to see the performance of the biologics testing business modestly improve and return to growth in the fourth quarter after a year that was impacted by lowest sample volumes from several large clients due to project delays or regulatory challenges.
我們很高興地看到,在經歷了因專案延誤或監管挑戰導致幾家大客戶樣本量最低的一年後,生物製劑檢測業務的業績在第四季度略有改善並恢復成長。
The manufacturing segment's operating margin increased by 340 basis points to 32.1% in the fourth quarter and by 140 basis points to 28.8% for the full year. We were pleased that the segment's operating margin continued to improve and move closer to the 30% level in 2025, driven principally by a solid performance from the microbial solutions business, as well as restructuring actions to generate incremental cost savings, including in the CDMO business.
製造業部門第四季營業利益率成長 340 個基點至 32.1%,全年營業利潤率成長 140 個基點至 28.8%。我們很高興看到,該業務板塊的營業利潤率持續改善,並預計在 2025 年達到 30% 的目標水平,這主要得益於微生物解決方案業務的穩健表現,以及為實現成本節約而採取的重組措施,包括 CDMO 業務的重組。
Before I hand the call over to Birgit to discuss our 2026 guidance, I'd like to take a moment to reflect on my long and fulfilling career at Charles River. As many of in January, I announced my planned retirement effective at the conclusion of our annual meeting of shareholders on May 5, but I am pleased to remain on our Board.
在將電話交給 Birgit 討論我們 2026 年的指導方針之前,我想花點時間回顧一下我在 Charles River 漫長而充實的職業生涯。和許多人一樣,我在一月份宣布了我計劃於 5 月 5 日年度股東大會結束後退休,但我很高興能夠繼續留在董事會。
Leading the extraordinary team at Charles River as CEO for more than 30 years has been a profound experience and one of the greatest privileges of my life. Together, we built an industry leader with a culture shaped by a remarkable people, a strong and supportive workplace, and world-class science, all of which has enabled us to deliver meaningful outcomes for our clients and patients who rely on us.
擔任查爾斯河公司執行長超過 30 年,領導這支卓越的團隊,對我來說是一段意義非凡的經歷,也是我人生中最榮幸的事情之一。我們共同打造了行業領導者,其文化由傑出的人才、強大而支持性的工作場所和世界一流的科學所塑造,所有這些都使我們能夠為依賴我們的客戶和患者帶來有意義的成果。
Well, I'm proud of our accomplishments from taking the company public on the New York Stock Exchange to transforming Charles River into a global leader in pre-clinical drug development services, and then becoming a respected member of the S&P 500. I am most proud and appreciative of the relationships that I have built over the last five decades with my colleagues, our clients, and all of you, our shareholders and analysts. I sincerely thank you.
我為我們所取得的成就感到自豪,從帶領公司在紐約證券交易所上市,到將查爾斯河公司轉型為臨床前藥物開發服務的全球領導者,再到成為標準普爾 500 指數中備受尊敬的成員。在過去的五十年裡,我與同事、客戶以及各位股東和分析師建立了深厚的友誼,我為此感到無比自豪和感激。我衷心感謝你。
We have made tremendous progress over the last 12 months, ranging from NAMs and NHP supply to the biopharma Demand Environment and our strategic review, making this the right time to transition the company into its next chapter.
在過去的 12 個月裡,我們在 NAM 和 NHP 供應、生物製藥需求環境以及我們的策略審查等方面都取得了巨大的進步,這使得現在成為公司邁入下一個階段的合適時機。
I'm delighted that Birgit Girshick will become our next CEO and it will be in her capable hands to drive forward Charles River's strategic direction, future growth, and operational excellence for many years to come.
我很高興 Birgit Girshick 將成為我們的下一任首席執行官,相信在她有能力的領導下,Charles River 將在未來許多年裡繼續推進戰略方向、未來成長和卓越營運。
Birgit has played an instrumental role as COO for nearly five years, leading our global businesses, guiding our digital evolution, and most recently, driving our strategic vision. I have worked closely with Birgit for many years and have the utmost confidence in her leadership abilities, and I will continue to work closely with her in the coming months to ensure a seamless transition.
在過去的近五年裡,Birgit 擔任營運官,發揮了至關重要的作用,領導著我們的全球業務,指導著我們的數位轉型,最近也推動了我們的策略願景。多年來,我一直與比爾吉特密切合作,對她的領導能力充滿信心,在接下來的幾個月裡,我將繼續與她密切合作,以確保平穩過渡。
As I sign off on my final earnings call, I'd like to thank our employees profoundly for their exceptional work and commitment. It is their dedication to exquisite science and exceptional client service that has distinguished us as the preeminent provider of pre-clinical services.
在我結束最後一次財報電話會議之際,我衷心感謝我們的員工們所付出的卓越努力和奉獻精神。正是他們對精湛科學和卓越客戶服務的執著追求,使我們成為臨床前服務的傑出提供者。
And always, I thank our clients and shareholders for their support over the years. Now, I will introduce our next CEO, Birgit Girshick, who will provide details on our 2026 financial guidance.
最後,我始終感謝客戶和股東多年來的支持。現在,我將介紹我們的下一任執行長比爾吉特·吉爾希克,她將詳細介紹我們 2026 年的財務預期。
Birgit Girshick - Executive Vice President and Chief Operating Officer
Birgit Girshick - Executive Vice President and Chief Operating Officer
Good morning, everyone. First, I want to sincerely thank you, Jim, for the tremendous mentorship and close partnership you have provided over the years to prepare me for this incredible opportunity and also for your significant contributions to build the company into the industry leader that we are today.
各位早安。首先,我要真誠地感謝吉姆,感謝你多年來給予我的巨大指導和緊密合作,使我為這個難得的機會做好了準備;同時,我也要感謝你為公司發展成為如今的行業領導者所做出的重大貢獻。
I also want to thank and acknowledge our Board of Directors for the trust that they have placed in me.
我還要感謝董事會對我的信任。
I'm deeply honored to become Charles River's next CEO and am committed to building upon the solid foundation that Jim has established. With a talented team at Charles River, we will continue to work tirelessly to lead the industry, to accelerate the progress we have made in scientific innovation, to advance drug development through our best in class science and client service, and by continuing to focus on ensuring the company remains leading edge with world-class processes, a client-centric service offering, and technology enablement.
我深感榮幸能夠成為查爾斯河公司的下一任首席執行官,並將致力於在吉姆奠定的堅實基礎上繼續發展。憑藉查爾斯河公司才華橫溢的團隊,我們將繼續不懈努力,引領行業發展,加速我們在科學創新方面取得的進展,透過我們一流的科學和客戶服務推進藥物研發,並繼續專注於確保公司在世界一流的流程、以客戶為中心的服務以及技術賦能方面保持領先地位。
I am very excited to be Charles River's next phase of growth. I will now provide details on our 2026 financial guidance and the improving trends that we expect. Organic revenue in 2026 is expected to range from down 1% to at least flat compared to a 1.6% decline in 2025. We expect the operating margin will improve by 20 basis points to 50 basis points from 19.8% in 2025, driven principally by the benefits from the acquisition of the assets of KF Cambodia.
我非常興奮能夠成為查爾斯河公司下一個發展階段的一份子。接下來,我將詳細介紹我們 2026 年的財務預期以及我們預期的改善趨勢。預計 2026 年有機收入將下降 1% 至至少持平,而 2025 年的下降幅度為 1.6%。我們預計,到 2025 年,營業利潤率將從 19.8% 提高 20 個基點至 50 個基點,這主要得益於收購 KF Cambodia 資產帶來的收益。
This is expected to translate into non-GAAP earnings per share in a range from $10.70 to $11.20 representing growth of approximately 4% to 9%. We continue to expect that the acquisition will add approximately $0.25 to earnings per share this year, which has been embedded in this guidance. By segment, we expect our mass revenue to decline at a low to mid-single-digit on an organic basis in 2026. There are two primary factors driving the decline.
預計這將轉化為每股非GAAP收益在10.70美元至11.20美元之間,成長約4%至9%。我們仍預期此次收購將使今年的每股盈餘增加約 0.25 美元,這一預期已包含在本次業績指引中。以細分市場來看,我們預期 2026 年大眾市場收入將出現低至中等個位數的自然下降。導致這種下降趨勢的主要因素有兩個。
First, NHP revenue is expected to be below 2025 levels and represents an approximate 200 basis point headwind to the RMS growth rate. This is primarily due to the timing of shipments which favor 2025 and will have a particularly significant impact on the year over year comparison in the first quarter of 2026.
首先,預計 NHP 收入將低於 2025 年的水平,這將對 RMS 成長率造成約 200 個基點的不利影響。這主要是由於出貨時間安排有利於 2025 年,並將對 2026 年第一季的同比數據產生特別顯著的影響。
A reduction in NHP volume commitments to certain third-party clients will also affect the growth rate. The other meaningful arm as headwind in 2026 will be cradle occupancy levels, which are expected to continue to be constrained as demand from early stage biotech clients remains subdued.
對某些第三方客戶的 NHP 銷售承諾減少也會影響成長率。2026 年另一個重要的不利因素是育肥場佔用率,育肥場佔用率預計將繼續受到限制,因為早期生技客戶的需求仍然低迷。
Global revenue for small research models is expected to be flat to slightly higher in 2026 as unit volumes declines, particularly in North America, and will continue to be offset by favorable pricing. We expect TSA revenue will be in a range between slightly positive and a low single-digit decrease on an organic basis in 2026.
由於銷量下降,尤其是在北美地區,預計 2026 年小型研究模型的全球收入將持平或略有增長,但有利的價格將繼續抵消銷售下降的影響。我們預計,2026 年 TSA 的收入將略有成長或出現個位數百分比的下降(以自然成長計算)。
As Jim discussed, we are cautiously optimistic that the favorable DSA demand trends will continue in 2026, supported by the recent improvement in biotech funding. We believe the strong bookings performance at the end of 2025 and a continuation of favorable trends this year will result in a return to DSA organic revenue growth in the second half of 2026.
正如吉姆所討論的那樣,我們謹慎樂觀地認為,在生物技術資金近期改善的支持下,DSA 的有利需求趨勢將在 2026 年繼續保持。我們相信,2025 年底強勁的預訂業績以及今年有利趨勢的延續,將使 DSA 在 2026 年下半年恢復有機收入成長。
In order to achieve the top end of our DSA revenue outlook for the year, it would require continued momentum in the bookings environment, resulting in the net book to bill averaging above one times for the year. This does not mean that every quarter will be above one time, as our business isn't linear, and factors like backlog conversion and the timing of bookings or study starts also heavily influence the DSA growth potential.
為了實現我們今年的DSA收入預期最高目標,需要預訂環境保持持續增長勢頭,從而使全年淨訂單額與賬單額的平均比率超過1倍。這並不意味著每個季度都會超過 1 倍,因為我們的業務並非線性成長,積壓訂單轉換率以及預訂或學習開始的時間等因素也會對 DSA 的成長潛力產生重大影響。
For the manufacturing segment, we expect the organic revenue growth rate will rebound to a low single-digit increase this year. This favorable outlook compared to a 1.6% organic decline last year, principally reflects the anniversary of the loss of a commercial cell therapy client whose program generated about $20 million in CDMO revenue during the first half of 2025.
對於製造業領域,我們預計今年的有機收入成長率將反彈至個位數低點成長。與去年 1.6% 的有機下滑相比,這一有利的前景主要反映了商業細胞療法客戶流失週年紀念日,該客戶的項目在 2025 年上半年產生了約 2000 萬美元的 CDMO 收入。
Microbial Solutions is expected to report a growth rate in the mid-single-digits, similar to its 2025 levels. And we expect that some of the clients specific challenges that impacted the biologics testing growth rate last year will be alleviated, resulting in a slightly better performance in 2026. Moving on to operating margin. We expect that the DSA segment will be the primary driver of the 20 basis points to 50 basis points of consolidated marginal improvement in 2026.
微生物解決方案公司預計將實現中等個位數的成長率,與 2025 年的水準相似。我們預計,去年影響生物製劑檢測成長率的一些客戶具體挑戰將會得到緩解,使 2026 年的業績略有改善。接下來分析營業利益率。我們預計,DSA 業務部門將是 2026 年綜合邊際收益提高 20 至 50 個基點的主要驅動力。
As previously mentioned, the margin expansion will largely be driven by the acquisition of KF, as lower sourcing costs to procure NHPs to support DSA studies will generate meaningful marginal improvement in the second half of the year once the models source post acquisition begins to be placed on studies.
如前所述,利潤率的擴張將主要由收購 KF 推動,因為收購後採購的 NHP 用於支持 DSA 研究的採購成本降低,將在下半年產生顯著的邊際改善,屆時這些模型將開始用於研究。
For the year, we expect KF acquisition will benefit the operating margin by more than 50 basis points on a consolidated basis and by more than 100 basis points in the DSA segment. We expect the RMS and manufacturing operating margins will be stable in 2026.
今年,我們預計 KF 的收購將使合併後的營業利潤率提高 50 個基點以上,DSA 業務部門的營業利潤率提高 100 個基點以上。我們預計 2026 年 RMS 和製造業務的營業利潤率將保持穩定。
From an earnings perspective, we expect most of the earnings per share improvement in 2026 will be generated from operations driven by margin expansion. We expect to generate at least $100 million in incremental cost savings above the 2025 level to help protect the operating margin because revenue growth will not offset the level of annual cost inflation this year.
從獲利角度來看,我們預計 2026 年每股盈餘的大部分成長將來自利潤率擴張帶來的營運成長。我們預計到 2025 年,成本節約將增加至少 1 億美元,以幫助保護營業利潤率,因為今年的收入成長將無法抵消年度成本上漲的幅度。
As we discussed in November, the incremental savings will be primarily driven by initiatives designed to drive greater operating efficiencies through process improvement, procurement synergies, and implementation of an integrated global business services approach.
正如我們在 11 月討論的那樣,新增節省將主要透過旨在提高營運效率的舉措來實現,這些舉措包括流程改進、採購協同效應以及實施一體化的全球業務服務方法。
As a reminder, we are now expected to generate a cumulative total of over $300 million in cost savings on an annualized basis based on actions that we implemented over the last three years. I have personally led many of the company's efforts to reduce costs through restructuring and efficiency initiatives designed to keep cost structure aligned with the pace of demand and to drive process improvement. I will continue to focus on streamlining our processes and ensuring we operate in nimble, responsive, and technology-enabled organization going forward.
提醒大家,根據我們過去三年採取的措施,預計我們每年累積可節省超過 3 億美元的成本。我親自領導了公司許多降低成本的工作,透過重組和提高效率的舉措,使成本結構與需求速度保持一致,並推動流程改善。我將繼續專注於簡化我們的流程,並確保我們今後在一個靈活、響應迅速且技術驅動的組織中運作。
In addition to significant cost savings and the $0.25 per share benefit from the KF acquisition this year, below the line items are expected to contribute more than a $0.30 benefit at midpoint to 2026 earnings per share, principally driven by a lower tax rate.
除了今年從 KF 收購中獲得的顯著成本節約和每股 0.25 美元的收益外,預計以下項目將在 2026 年中期為每股收益貢獻超過 0.30 美元的收益,這主要是由於較低的稅率。
We expect the first quarter operating margin will be in the mid-teens, pressured by a few discrete factors, including an unfavorable mix from the timing of NHP shipments in the RMs segment, the acceleration of stock compensation expense to do the CEO transition, and higher DSA costs primarily related to NHP sourcing and staffing.
我們預計第一季營業利潤率將在十幾個百分點點左右,受到一些具體因素的影響,包括RM部門NHP出貨時間安排不利導致的產品組合、CEO過渡期間加速的股票補償支出,以及主要與NHP採購和人員配備相關的DSA成本上升。
These factors are not expected to be a meaningful headwind after the first quarter, and we expect the operating margin will improve significantly thereafter. Mike will provide additional details on our first quarter outlook as well as the below the line items shortly.
預計這些因素在第一季之後不會構成實質的不利影響,我們預計此後營業利潤率將顯著提高。Mike 稍後將提供更多關於我們第一季展望以及以下項目的詳情。
Before I conclude, I'm pleased to announce that we will be adding two experienced senior leaders to our team this spring. Glenn Coleman will join us on April 6 as executive Vice President and Chief Financial Officer.
最後,我很高興地宣布,今年春天我們將為團隊增添兩位經驗豐富的資深領導。Glenn Coleman 將於 4 月 6 日加入我們,擔任執行副總裁兼財務長。
Glenn is a seasoned financial leader and operationally oriented CFO with over a decade of experience in the healthcare industry. Glenn has over 30 years of strong financial and operational management experience and has been CFO for multiple public companies as well as a Chief Operating Officer with experience managing clinical, R&D, and manufacturing teams.
Glenn 是一位經驗豐富的財務領導者和營運導向財務官,在醫療保健行業擁有十多年的經驗。Glenn 擁有超過 30 年的強大財務和營運管理經驗,曾擔任多家上市公司的財務官,以及首席營運官,擁有管理臨床、研發和製造團隊的經驗。
I also would like to thank Mike now for his leadership of our finance organization during the CFO search. Mike will continue in his current position as senior Vice President and Chief Accounting Officer and will play an instrumental role in the success of our organization. I'm grateful for his dedication and commitment to Charles River.
我還要感謝 Mike 在尋找財務長期間對我們財務部門的領導。麥克將繼續擔任高級副總裁兼首席會計官一職,並將為我們組織的成功發揮重要作用。我感謝他對查爾斯河的奉獻和投入。
We are also pleased to have Carrie Daley join us on March 30 as Senior Vice President and Chief Legal Officer. Carrie brings 25 years of sophisticated legal experience to Charles River and is an experienced leader that has been focused on advising multinational life science companies across complex regulatory environments.
我們也很高興地宣布,Carrie Daley 將於 3 月 30 日加入我們,擔任高級副總裁兼首席法務官。Carrie 為 Charles River 帶來了 25 年豐富的法律經驗,她是一位經驗豐富的領導者,一直致力於為跨國生命科學公司在複雜的監管環境下提供諮詢服務。
We are pleased that you will enable us to proactively manage our highly regulated science-led organization by combining our legal, compliance, communications, government relations, security, and ESG initiatives under one leader. I look forward to welcoming and partnering with both Glenn and Carrie in the coming months.
我們很高興您將使我們能夠透過將我們的法律、合規、溝通、政府關係、安全和 ESG 舉措整合到一個領導者之下,從而積極管理我們這個受嚴格監管的科學主導型組織。我期待在接下來的幾個月裡歡迎格倫和凱莉的加入,並與他們合作。
I would also like to reiterate my appreciation for being named Charles Rivers' next CEO. It is an honor that I'm proud to accept. I am firm in my commitment to drive forward the company's strategic direction and growth imperatives, including the actions that we outlined in November to enhance long-term shareholder value.
我還要再次感謝查爾斯·里弗斯公司任命我為下一任執行長。我非常榮幸能夠接受這份榮譽。我將堅定不移地推動公司的策略方向和成長要務,包括我們在 11 月提出的旨在提升股東長期價值的各項措施。
Over the past five years and more, I've had the pleasure of meeting many of you at various investor conferences and related events. These interactions have provided valuable opportunities to exchange ideas and insights, which I look forward to continuing. I'm eager to reconnect with those of you I have met previously, and for those whom I have not yet had the chance to meet, I look forward to doing so in the coming months. I'm committed to maintaining open and transparent communication with our investor community and welcome the opportunity to introduce myself and discuss our vision for the future of Charles River. Now I will turn the call over to our Interim CFO, Mike Knell.
在過去的五年多時間裡,我很高興在各種投資者會議及相關活動中結識了各位。這些交流為我提供了寶貴的交流想法和見解的機會,我期待繼續進行這些交流。我非常期待與之前見過面的朋友們重新建立聯繫,對於那些我還沒有機會見面的朋友,我期待在接下來的幾個月與他們見面。我致力於與投資者群體保持公開透明的溝通,並歡迎有機會向大家介紹我自己,並探討我們對查爾斯河未來發展的願景。現在我將把電話交給我們的臨時財務長邁克·克內爾。
Thank you.
謝謝。
Michael Knell - Interim Chief Financial Officer
Michael Knell - Interim Chief Financial Officer
Good morning and thank you, Birgit. It's been an honor to lead our talented finance team for the last several months, and I look forward to continuing to work closely with them and our new CFO to drive our future success. I would also like to thank you, Jim, and the board for the opportunity to be interim CFO.
早上好,謝謝你,比爾吉特。在過去的幾個月裡,我很榮幸能夠領導我們才華橫溢的財務團隊,我期待著繼續與他們以及我們的新財務長密切合作,推動我們未來的成功。我還要感謝吉姆和董事會給予我擔任臨時財務長的機會。
Before I begin, may I remind you that I'll be speaking primarily to non-GAAP results, which exclude amortization and other acquisition related adjustments, impairments, costs related primarily to restructuring initiatives, gains or losses from certain venture capital and other strategic investments, and certain other items. Many of my comments will also refer to organic revenue growth, which excludes the impact of acquisitions, divestitures, and foreign currency translation.
在開始之前,請允許我提醒各位,我將主要談論非GAAP業績,其中不包括攤銷和其他收購相關調整、減值、主要與重組計劃相關的成本、某些風險投資和其他戰略投資的收益或損失以及某些其他項目。我的許多評論還會提到有機收入成長,這不包括收購、剝離和外幣折算的影響。
Let me start by providing some additional details on our 2026 guidance. Birgit get highlighted our organic revenue growth and non-GAAP earnings per share outlooks. On a reported basis, we expect revenue will be between at least flat and 1.5% growth.
首先,讓我提供一些關於我們 2026 年指導方針的補充細節。Birgit重點介紹了我們的有機收入成長和非GAAP每股收益展望。據報告顯示,我們預計營收至少將持平或成長 1.5%。
FX is expected to be a tailwind as the US dollar has continued to weaken and is expected to benefit reported revenue by 1% to 1.5%. We also expect a small revenue benefit from PathoQuest once the acquisition closes later this quarter.
由於美元持續走弱,外匯市場預計將成為利好因素,預計將使報告收入增加 1% 至 1.5%。我們也預計,在本季度稍後完成對 PathoQuest 的收購後,我們將獲得少量收入成長。
We have provided additional information on FX rates and our currency exposure in the appendix of our slide presentation. On slide 31, we have also provided the segment outlook for 2026, which includes reported and organic revenue expectations. As Birgit mentioned, we expect several headwinds to impact the first quarter operating margin and earnings per share.
我們在幻燈片簡報的附錄中提供了有關外匯匯率和我們貨幣風險敞口的更多資訊。在第 31 頁幻燈片中,我們還提供了 2026 年的業務展望,其中包括報告收入和有機收入預期。正如 Birgit 所提到的,我們預計有幾個不利因素將影響第一季的營業利潤率和每股盈餘。
Our outlook for the first quarter of 2026 assumes revenue will be essentially flat to slightly negative on a reported basis and will decline at a low single-digit rate on an organic basis. By segment, the RMS growth rate will be negatively impacted by lower NHP revenue due primarily to the timing of shipments, which will have a nearly $10 million impact on first quarter RMS revenue.
我們對 2026 年第一季的展望是,按報告數據計算,收入將基本持平或略有下降,按有機增長計算,收入將以較低的個位數速度下降。以業務板塊來看,由於出貨時間的原因,NHP 營收下降將對 RMS 成長率產生負面影響,這將對第一季 RMS 營收造成近 1,000 萬美元的影響。
The manufacturing segment's growth rate will reflect the difficult year over year comparison with regard to commercial revenue in the CDMO business, which also has an approximately $10 million impact on first quarter manufacturing revenue.
製造業部門的成長率將反映出 CDMO 業務商業收入同比比較困難的情況,這也對第一季製造業收入產生了約 1000 萬美元的影響。
We expect the DSA rate of decline will improve slightly from second half 2025 levels, but as a reminder, the benefit from strong bookings activity in the fourth quarter will not yet be evident in DSA revenue in the first quarter.
我們預計 DSA 的下降速度將從 2025 年下半年的水平略有改善,但需要提醒的是,第四季度強勁的預訂活動帶來的好處在第一季的 DSA 收入中還不會顯現出來。
From a first quarter earnings perspective, we expect non-GAAP earnings per share will decline at a high-teens rate year over year. As Birgit mentioned, there are several discrete factors that will impact the operating margin in the first quarter, resulting in an operating margin in the mid-teens.
從第一季獲利的角度來看,我們預期非GAAP每股盈餘將年減10%以上。正如 Birgit 所提到的,有幾個獨立的因素會影響第一季的營業利潤率,導致營業利潤率約為十幾個百分點。
The two primary factors are the timing of NHP shipments and higher stock compensation costs due largely to an acceleration of the expense related to the CEO transition. Stock compensation is expected to approximate a $0.15 headwind to EPS in the first quarter.
兩個主要因素是 NHP 出貨時間以及由於 CEO 過渡相關費用加速增加而導致的更高的股票補償成本。預計股票補償將使第一季每股收益下降約 0.15 美元。
In addition, the DSA margin will continue to be pressured in the first quarter as it was in the fourth quarter by higher NHP sourcing costs due to higher than anticipated demand for these studies, as well as increased staffing costs, but these DSA headwinds are expected to dissipate after the first quarter.
此外,由於這些研究的需求高於預期,導致 NHP 採購成本上升,以及人員配備成本增加,DSA 利潤率在第一季將繼續受到壓力,就像第四季度一樣,但預計這些 DSA 的不利因素將在第一季後消散。
Normalizing NHP study related costs due in part to the KF acquisition, improving demand trends, and the strong year end bookings are expected to benefit revenue and generate sequential improvement in the DSA operating margin as the year progresses.
由於 KF 收購、需求趨勢改善以及年底強勁的預訂,NHP 研究相關成本正常化預計將有利於收入,並隨著時間的推移,DSA 的營業利潤率將逐年提高。
I will now provide details on non-operating items.
接下來我將詳細介紹非營運項目。
Unallocated corporate costs in 2026 are expected to be similar to the 5.5% of total revenue reported in 2025. We expect unallocated corporate costs in the first quarter to be elevated due to the timing of stock compensation expense related to the CEO transition, but this does not have a meaningful impact on the full year.
預計 2026 年未分配的公司成本將與 2025 年報告的總收入的 5.5% 相似。我們預計第一季未分配的公司成本會因與執行長過渡相關的股票補償費用的時間安排而升高,但這不會對全年產生實質影響。
For the remainder of the year, we expect unallocated corporate costs to trend favorably because of the benefit from prior cost saving initiatives, and performance-based bonus accruals are expected to be lower as targets are reset for the new year.
今年剩餘時間裡,我們預計未分配的公司成本將呈現有利趨勢,因為先前的成本節約措施帶來了好處;同時,由於新一年的目標重新設定,基於績效的獎金應計額預計將會降低。
The non-GAAP tax rate for 2026 is expected to be in the range of 22% to 23%, a decrease from 24.6% in 2025. The anticipated decrease in the tax rate is primarily driven by the 2026 tax rate benefits related to the enactment of the One Big Beautiful Bill Act or OB3 and a favorable geographic mix.
預計 2026 年的非 GAAP 稅率將在 22% 至 23% 之間,低於 2025 年的 24.6%。預計稅率下降的主要原因是 2026 年《一項偉大的法案》(OB3)的頒布帶來的稅率優惠以及有利的地域組合。
In 2025 we lowered our net interest expense by shifting debt to lower interest rate geographies and by repaying debt borrowed for stock repurchases earlier in the year. At the end of the fourth quarter, we had outstanding debt of $2.1 billion with approximately 70% at a fixed interest rate compared to $2.2 billion at the end of 2024. This equated to a gross leverage ratio of 2.1 times and a net leverage ratio of 2.0 times at the end of the fourth quarter.
2025 年,我們透過將債務轉移到利率較低的地區以及償還年初為股票回購而藉入的債務,降低了淨利息支出。截至第四季末,我們的未償債務為 21 億美元,其中約 70% 為固定利率債務,而到 2024 年底,未償債務將達到 22 億美元。第四季末,總槓桿率為 2.1 倍,淨槓桿率為 2.0 倍。
We expect gross and net leverage ratios will remain below 3 times after funding the KF and PathoQuest acquisitions. Total adjusted net interest expense in 2026 is expected to be in a range of $95 million to $100 million compared to $102.1 million last year.
我們預計在為收購 KF 和 PathoQuest 提供資金後,總槓桿率和淨槓桿率將保持在 3 倍以下。預計 2026 年調整後淨利息支出總額將在 9,500 萬美元至 1 億美元之間,而去年為 1.021 億美元。
We expect higher average debt balances in 2026 as a result of the KF and PathoQuest acquisitions, but the decrease in net interest expense reflects the full year benefit of 2025 interest rate reductions in the favorable geographic interest rate mix.
我們預計,由於收購 KF 和 PathoQuest,2026 年平均債務餘額將會增加,但淨利息支出的減少反映了 2025 年利率下調帶來的有利的地域利率組合的全年收益。
As we discussed in November, we will continue to take a disciplined approach to capital deployment and plan to regularly evaluate the optimal balance between acquisitions, debt repayment, stock repurchases, and other uses of cash.
正如我們在 11 月討論的那樣,我們將繼續採取嚴謹的資本部署方式,並計劃定期評估收購、償還債務、股票回購和其他現金用途之間的最佳平衡。
For 2026, with the deployment of over $500 million in capital for the KF and PathoQuest acquisitions, we currently intend to focus more on debt repayment and maintaining dry powder as we continue to evaluate potential M&A opportunities.
2026 年,由於已投入超過 5 億美元的資金用於收購 KF 和 PathoQuest,我們目前打算將更多精力放在償還債務和保持可用資金上,同時繼續評估潛在的併購機會。
We will also continue to regularly evaluate all uses of capital throughout the year, including stock repurchases. However, we currently expect the average diluted share count will be slightly higher in 2026. For 2026, we expect free cash flow will be in a range of $375 million to $400 million representing a decrease from $518.5 million in 2025.
我們將繼續全年定期評估所有資金用途,包括股票回購。不過,我們目前預計 2026 年平均稀釋股份數量將略高一些。我們預計 2026 年的自由現金流將在 3.75 億美元至 4 億美元之間,比 2025 年的 5.185 億美元減少。
The decrease primarily reflects two main drivers higher performance-based cash bonus payments due to the 2025 outperformance, which are paid in the first quarter of 2026, and deferred compensation payments related to the planned CEO retirement.
下降主要反映了兩個主要因素:一是由於 2025 年業績超預期,績效現金獎金支付增加(將於 2026 年第一季度支付);二是與執行長計畫退休相關的遞延補償金支付。
Capital expenditures for 2026 are expected to be approximately $200 million or approximately 5% of total revenue and a slight reduction from the 2025 level of $219.2 million. This outlook reflects our disciplined approach to managing capital investments while continuing to invest strategically in areas to support client demand.
預計 2026 年的資本支出約為 2 億美元,約佔總收入的 5%,比 2025 年的 2.192 億美元略有下降。這一觀點反映了我們在管理資本投資方面採取的嚴謹方法,同時我們將繼續在能夠滿足客戶需求的領域進行策略性投資。
A summary of our 2026 financial guidance can be found on slide 39. In conclusion, we remain encouraged by the recent demand trends and by the potential to return to organic revenue growth in the second half of the year.
有關我們 2026 年財務指導的摘要,請參閱第 39 頁投影片。總之,我們對近期的需求趨勢以及下半年恢復有機收入成長的潛力感到鼓舞。
We are laser focused on driving our strategy forward, including through selective and strategic M&A that aligns with our core competencies, taking decisive actions to deliver continued benefits to drive efficiency and process improvements that will strengthen our organization and enhance our flexibility as demand rebounds and through maintaining a disciplined capital allocation approach. These actions position us well to drive long-term shareholder value creation.
我們正全力推動我們的策略,包括透過與我們核心競爭力相符的選擇性策略併購,採取果斷行動,持續帶來效益,提高效率和流程改進,從而增強我們的組織實力,並在需求反彈時提高我們的靈活性,同時保持嚴謹的資本配置方法。這些舉措使我們能夠更好地推動股東價值的長期創造。
Finally, I want to thank Jim for his tremendous leadership and many contributions during my time at Charles River and throughout his career. And we look forward to continuing to execute on our strategy under Birgit's leadership. Thank you.
最後,我要感謝吉姆在我任職查爾斯河期間以及他整個職業生涯中展現出的卓越領導能力和許多貢獻。我們期待在比爾吉特的領導下繼續執行我們的策略。謝謝。
Todd Spencer - Corporate Vice President, Investor Relations
Todd Spencer - Corporate Vice President, Investor Relations
That concludes our comments. We will now take your questions.
我們的發言到此結束。現在開始回答各位的問題。
Operator
Operator
Thank you. (Operator Instructions) Eric Coldwell, Baird.
謝謝。(操作說明)埃里克·科德威爾,貝爾德。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
Thanks very much. I wanted to dig into, the broader topic of NHPs. There seemed to be some, I don't know, dichotomy in the outlook and results here between RMS and DSA hoping you can just walk us through this and help clear it up.
非常感謝。我想深入探討非人靈長類動物這個更廣泛的主題。RMS 和 DSA 在前景和結果方面似乎存在一些分歧,我不知道該怎麼說,希望您能為我們解釋一下,幫助我們澄清一下。
So, RMS is facing, material headwind from lower NHP volume, we've also heard lower sales from one of your competitors, but. At the same time, DSA is facing a material headwind from higher NHP sourcing costs and strong demand for NHP studies.
因此,RMS 面臨 NHP 銷售下降帶來的實質不利影響,我們也聽說你們的一位競爭對手的銷量有所下降,但是。同時,DSA 正面臨來自 NHP 採購成本上升和 NHP 研究需求強勁的實質阻力。
So, I'm just hoping you can walk us through some of these dynamics, the nuances between what's happening in RMS and what's happening in DSA, and then talk about, some of the drivers of the higher sourcing costs that are impacting you in the near term. Thanks very much.
所以,我希望您能帶我們了解這些動態,RMS 和 DSA 中正在發生的事情之間的細微差別,然後談談近期影響您的採購成本上升的一些驅動因素。非常感謝。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
You guys want to take that?
你們想拿那個嗎?
Birgit Girshick - Executive Vice President and Chief Operating Officer
Birgit Girshick - Executive Vice President and Chief Operating Officer
Yeah, happy to take it. Hi, Eric. Let me start with the RMS volume. So the RMS volumes, the impact in Q4 is, primarily timing. So, looking, for the full year, the, shipments have shifted. So, and with that, Q4 was lighter than the year before. Looking forward, we talked about RMs volumes being a driver of less revenue in Q1. That is both timing as well as a little bit lower volumes.
好的,我很樂意接受。嗨,艾瑞克。我先從均方根值說起。因此,RMS銷售在第四季受到的影響主要在於時間因素。因此,縱觀全年,出貨量已經改變了。因此,第四季比上年同期有所減輕。展望未來,我們討論了RM銷售將導致第一季營收減少。這既包括時機上的考量,也包括略低的銷售量。
For our DSA business, we talked about higher sourcing cost, particularly in Q4, having some impact in Q1. We had more NHP studies, coming in than we had expected in 2025 and early 2006. So, with that, we had to go to the open market and buy some, NHPs at a higher price, which will have an impact on our ROI.
對於我們的DSA業務,我們討論了採購成本上升的問題,尤其是在第四季度,這會對第一季度產生一定影響。2025 年和 2006 年初,我們收到了比預期更多的 NHP 研究報告。因此,我們不得不去公開市場以更高的價格購買一些天然健康產品,這將對我們的投資報酬率產生影響。
Part of the disconnect or that what you're seeing here is also the fact that we have, always have two sources. So, an Asian source as well as the Mauritian source. And they don't always, connect, perfectly of what we have available and internally from our own farms versus what we have to buy on the open market.
造成這種脫節的部分原因,或者說你在這裡看到的現象,也是因為我們總是有兩個資訊來源。所以,既有亞洲來源,也有毛里求斯來源。而且,它們並不總是能完美地銜接起來,將我們自己農場內部的資源與我們在公開市場上購買的資源進行對比。
So it's really mostly timing as well as, timing between the RMS business shipments when they're coming in, but also what kind of source we're needing, how quickly we're needing them, and that we have to source from the open market, if that makes sense.
所以,這主要取決於時機,不僅包括 RMS 業務發貨的時機,還取決於我們需要什麼樣的貨源,我們需要多快才能收到貨,以及我們必須從公開市場採購,如果這樣說你能理解的話。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
What it does. And if I could just ask a follow-up, what is the, you provide in your appendix, the NHP, utilization for '24, and you gave an update for '25, which was a pretty notable growth.
它的功能。如果我能再問一個後續問題,您在附錄中提供的 2024 年 NHP 利用率是多少?您還提供了 2025 年的最新數據,成長相當顯著。
Is it too early or would you care to share your thoughts on the full year for internal demand, compared to that, data point provided in, '25?
現在談論全年內部需求是否為時過早?或者您是否願意分享您對全年內部需求的看法,並與 2025 年提供的數據點進行比較?
Birgit Girshick - Executive Vice President and Chief Operating Officer
Birgit Girshick - Executive Vice President and Chief Operating Officer
So the, for 2026, yeah, it's a little bit too early, we're really just starting the year, but for 2025 compared to 2024, what you're seeing here is, a higher number of NHP studies coming through, which is a little bit of mix, but also, substantiate the need for this very important research model and that this research model is here to stay for a long time which. Also, required us to, ascertain our supply chain and therefore, the KF Cambodia acquisition.
所以,對於 2026 年來說,現在還為時過早,我們才剛開始新的一年。但是,與 2024 年相比,2025 年的 NHP 研究數量有所增加,雖然結果良莠不齊,但也證實了這種非常重要的研究模式的必要性,並且這種研究模式將長期存在。此外,還需要我們確定我們的供應鏈,因此也需要確定對 KF 柬埔寨的收購。
Eric Coldwell - Analyst
Eric Coldwell - Analyst
Thanks very much.
非常感謝。
Operator
Operator
Thanks, Eric.
謝謝你,埃里克。
Thank you. Luke Sergott, Barclays.
謝謝。盧克·塞爾戈特,巴克萊銀行。
Luke Sergott - Analyst
Luke Sergott - Analyst
Great, thanks for the question guys so I just kind of want to talk about the, it's the backlog here and the the DSA bookings they're starting to ramp the continued strength there but you guys also hired ahead of what was expected to be that demand so.
太好了,謝謝大家的提問。我只是想談談積壓訂單和DSA預訂的情況,他們正在逐步增加訂單量,保持強勁勢頭,但你們的招聘也超過了預期的需求。
As bookings environment, baked within your guide continue to improve, can you talk about your hiring needs as you, continue to ramp whatever you're going to do on the DSA to exit the year, do you guys have enough or should we expect some type of pick up there? Just trying to right size with the cost outs plus the capacity utilization and your hiring needs of what's going forward.
隨著預訂環境(已內建於您的指南中)的不斷改善,您能否談談您的招募需求?隨著您在年底前繼續加大對DSA的投入,你們的人員是否充足,或者我們是否應該期待招聘人數有所增加?只是想在成本控制、產能利用率以及未來招募需求的基礎上,找到合適的規模。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
We, from a capacity point of view we have sort of two issues. We have physical capacity which is in pretty good shape right now, so we're not optimally using our facilities, which obviously that's a goal of ours, but still, as the hopefully the demand increases, we'll be able to utilize space that's already built and be able to fill that. We've been really careful for years actually, but really careful the last two or three years to get our head count in sync with demand and with our revenue, obviously this is a people business and it's more than half of our costs, and last year, in 2025, we had some incremental people in our lab. Science is building business and to fill vacant spots.
從產能角度來看,我們面臨兩個問題。我們目前的硬體設施狀況良好,所以我們還沒有充分利用這些設施,這顯然是我們的目標,但隨著需求的增長,我們將能夠利用已經建成的空間並填滿它們。實際上,多年來我們一直非常謹慎,尤其是在過去兩三年裡,我們格外謹慎地調整員工人數,使其與需求和收入保持同步。顯然,這是一個以人為本的行業,員工成本占我們總成本的一半以上。去年,也就是 2025 年,我們的實驗室增加了一些員工。科學正在為企業創造價值,並填補市場空缺。
So I think we're in good shape. Senior scientific staff and study directors and people like that are in particularly good shape and principally we're looking at direct labor. We need to bring direct labor on probably 25% before we actually need them because there's some training associated with that, but, we're quite confident we'll be able to do that in a measured fashion to both accommodate the work and not be a drag on our operating margins.
所以我覺得我們情況不錯。高階科學研究人員、研究主管等人員狀況都特別好,我們主要關注的是直接勞動力。我們需要在實際需要之前就引進大約 25% 的直接勞動力,因為這需要一些培訓,但是,我們非常有信心能夠以穩健的方式做到這一點,既能滿足工作需求,又不會拖累我們的營運利潤率。
Luke Sergott - Analyst
Luke Sergott - Analyst
Got you and kind of related to that and this is kind of the overall with the AI fears baked within the market and particularly within your business you kind of gave the number there from a FTE perspective of percentage of cost but you know as you guys continue to restructure, get more efficient, talk about, I don't think that there's AI risk, but clearly the market doesn't agree with me so kind of walk us through the bull case and why you aren't going to be impacted by any AI coming through, considering how much wet lab work you guys need to do.
我明白了,這跟之前說的有點關係。這其實就是市場,尤其是你們公司內部,對人工智慧的擔憂。你剛剛從全職員工(FTE)的角度給出了成本百分比的數據,但你知道,隨著你們不斷重組,提高效率,我認為人工智慧沒有風險,但顯然市場並不認同我的觀點。所以,請你告訴我們樂觀的理由,以及為什麼考慮到你們需要做大量的濕實驗室工作,你們不會受到任何人工智慧的影響。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
Yeah, so thanks for that. So we were frankly, surprised at the sort of violent share price reaction to the AMI AI conversation's been going on across multiple industries actually for the last couple of weeks. So it is what it is we. We get caught up in that and so, there's several things that, we would like to say about that. AI is a AMS and we're focused on the NAMS to the extent that the science is beneficial, the science is, additive, and we view AI as an enabling technology to support our work over a long-term and to complement it, but we don't, we don't see it as a disruptor.
是的,謝謝你。坦白說,我們對過去幾週以來多個行業圍繞 AMI AI 的討論所引發的劇烈股價反應感到驚訝。事情就是這樣。我們很容易陷入這種境地,所以,關於這一點,我們想說幾句。人工智慧是應用數學(AMS),我們專注於應用數學(NAMS),只要這項科學是有益的,是有益的,我們將其視為一種賦能技術,可以長期支持和補充我們的工作,但我們不認為它是一種顛覆性技術。
AI in discovery has been around for a while by many of our large clients, so that is not new. The conversations really have not changed at all. And so, you know, for us, AI and NAMS is sort of a broader, longer-term evolution rather than something that is immediate
人工智慧在發現領域的應用已經在我們的許多大客戶中存在一段時間了,所以這並不是什麼新鮮事。對話內容其實一點都沒變。所以,對我們而言,人工智慧和北美行動行銷系統(NAMS)是一個更廣泛、更長遠的發展過程,而不是立即的事情。
We continue to see ourselves as an essential and logical partner to help validates, including AI as they, if and when they become beneficial and additive, as I said, and so we hope to be able to run interference in a positive way for both our clients and the regulatory agencies, to validate these technologies, if they're beneficial.
我們始終認為自己是驗證技術(包括人工智慧)的重要且合理的合作夥伴,因為正如我所說,當這些技術變得有益且具有附加價值時,我們希望能夠以積極的方式為我們的客戶和監管機構提供幫助,以驗證這些技術是否有益。
So, the names are basically crude right now. AI is really early, there's a promise of AI that we think could be beneficial to discovery, and we don't quite see it in safety. We've had some investments in AI to virtual control groups which we talked about in our prepared remarks, some of our scientific report writing, our sales effectiveness. We have data scientists that they're working on this, so, we're embracing, I guess the bottom line for us is we're embracing alternative technologies, sort of, strategically, but the science will prevail.
所以,這些名字目前還很粗糙。人工智慧還處於非常早期的階段,人工智慧展現出巨大的潛力,我們認為它可能對科學發現有益,但我們並不完全看好它的安全性。我們在人工智慧領域進行了一些投資,用於建立虛擬對照組(我們在準備好的演講稿中談到了這一點)、撰寫一些科學報告以及提高銷售效率。我們有資料科學家在研究這個問題,所以,我想對我們來說,最重要的是,我們正在策略性地擁抱替代技術,但科學終將勝出。
So the extent to which these technologies are beneficial, right, we'll use them, we think we'll use them more, we, the whole industry in discovery to help our clients get to a lead compound faster. Hopefully that will have more molecules moving through pre-clinical talks and more molecules moving into the clinic and hopefully more molecules being approved.
因此,這些技術在多大程度上是有益的,對吧?我們會使用它們,我們認為我們會更多地使用它們,我們整個藥物發現行業都會使用它們,以幫助我們的客戶更快找到先導化合物。希望這能促使更多分子藥物進入臨床前研究階段,更多分子藥物進入臨床試驗階段,最終促使更多分子藥物獲得批准。
So we acknowledge it, we embrace it, we're participating in it. We actually don't see it as a threat to the company, and if these technologies are better in any way besides just being augmented, they'll be embraced by the whole industry definitely nothing's imminent.
所以我們承認它,我們接受它,我們參與其中。我們其實不認為這對公司構成威脅,而且如果這些技術除了增強現有技術之外還有其他方面的改進,它們肯定會被整個行業所接受,目前還沒有什麼迫在眉睫的事情發生。
Charles Rhyee - Analyst
Charles Rhyee - Analyst
Great thanks.
非常感謝。
Operator
Operator
Thank you. Max Smock, William Blair.
謝謝。馬克斯·斯莫克,威廉·布萊爾。
Christine Rains - Equity Analyst
Christine Rains - Equity Analyst
Hi, it's Christine Rains on for Max. Congratulations to both, Jim and Berge on what lies ahead. And for our question, just hoping you can give some context on DSA cancellations in the quarter. I think you said they were consistent with last quarter levels, but here. Curious if they were within your normal range and if you could remind us what your normal range of range of cancellations is, and also if the distribution of cancellations due to client funding versus clinical and other competitive reasons, we're in line with expectations in the quarter. Thanks.
大家好,我是克莉絲汀‧雷恩斯,為您帶來Max的報道。恭喜吉姆和伯格,祝福他們未來一切順利。至於我們的問題,希望您能提供一些關於本季DSA取消的背景資訊。我想你說過它們與上季度的水平一致,但是這裡。想知道這些取消是否在您的正常範圍內,能否提醒我們您正常的取消範圍是多少,以及由於客戶資金、臨床和其他競爭原因導致的取消分佈情況,我們本季是否符合預期。謝謝。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
So cancellation, cancellations and slippage as we call it, are sort of. Elements of the of our business, so slippage is when, studies don't start when we anticipated they would start or when the clients initially anticipate, and things just canceled because.
所以,取消、取消和延誤,正如我們所說的,是某種程度上的。我們業務的某些方面,例如進度延誤,是指研究沒有在我們預期的時間開始,或者沒有在客戶最初預期的時間開始,導致一些事情被取消。
I don't know. Priorities change, therapeutic area focuses changes, or the drug just isn't performing well before we even get a hold of it. The clients just can't get it to a a dosage that won't be harmful to patients. So we have cancellations all the time and always will, we have penalties. For cancellations with insufficient notice, which, tends to cover whatever costs we've been impacted by, up to that point, and with a decent backlog, we managed this really well. There's very little variability, without a slippage or cancellation, so we've never given the actual percentage or dollar amount or whatever, nor will we, but we're definitely back to sort of normal.
我不知道。優先事項會改變,治療領域重點會改變,或者在我們拿到藥物之前,藥物本身的效果就不好。客戶始終無法找到對患者無害的劑量。所以,我們一直都有取消預訂的情況,而且這種情況以後也會一直存在,我們會收取罰款。對於通知時間不足的取消訂單,我們通常會支付由此造成的任何損失,而且由於積壓訂單量充足,我們處理得非常好。波動很小,沒有出現延誤或取消,所以我們從來沒有給出過實際的百分比或金額或其他任何數字,以後也不會給出,但我們肯定已經恢復到某種正常狀態了。
Expected anticipated, cancellations, and we can manage that really well again without the volatility in our business model and to be able to accommodate, clients across the board, both large pharma and biotech and the, cancel and just to go back to the. The sort of 9 months backlog we have now we like that. It gives us a really great line of sight. If a study cancels or slips, we can almost always, not always, but almost always be able to slot something in the queue into, real-time revenue generating work to replace whatever has slipped and canceled, so.
預計會出現取消,我們可以再次很好地應對這種情況,而不會出現商業模式的波動,並且能夠滿足所有客戶的需求,包括大型製藥公司和生物技術公司,取消訂單,然後恢復正常。我們喜歡現在這種積壓了9個月的工作量的情況。它給了我們非常好的視野。如果一項研究被取消或延期,我們幾乎總是可以(雖然並非總是如此,但幾乎總能)將一些即時產生收入的工作安排到隊列中,以取代任何延期或取消的工作。
As because you asked the question, cancellations had gotten a couple of years ago, much higher than we would have liked or we had seen historically, improved last year, and is now sort of back to normal levels, impossible to predict, but we wouldn't anticipate, given the sort of market dynamics, cash coming into biotech, pharma companies finishing sort of skimming down their portfolios. That they would increase again in any significant way.
因為你問了這個問題,幾年前取消訂單的情況比我們希望的或歷史上看到的要嚴重得多,去年有所改善,現在基本恢復到正常水平,雖然無法預測,但考慮到目前的市場動態,資金流入生物技術,製藥公司正在逐步精簡其產品組合,我們預計不會出現這種情況。它們會再次出現顯著增長。
Christine Rains - Equity Analyst
Christine Rains - Equity Analyst
Great, thank you.
太好了,謝謝。
Operator
Operator
Yeah.
是的。
Thank you. David Windley, Jefferies.
謝謝。David Windley,傑富瑞集團。
David Windley - Equity Analyst
David Windley - Equity Analyst
Hi, good morning. Thanks for taking my questions. Congrats, Jim. It's been a nice ride. I looked back at my initiation. I think this is 100 conference calls with you for, so thanks for the ride. .
您好,早安。謝謝您回答我的問題。恭喜你,吉姆。這段旅程很愉快。我回顧了我的入會儀式。我想這應該是我跟你第 100 次電話會議了,謝謝你們一路陪伴。。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
It's been a pleasure. It's been a pleasure, Dave.
非常榮幸。很高興認識你,戴夫。
David Windley - Equity Analyst
David Windley - Equity Analyst
My thank you. My question for you is basically a temperature check on demand or urgency of clients last year. You entered into '25 with some clients, kind of booking some fast burn, wanted to start quickly type studies. Your demand booked the bill in the fourth quarter certainly was strong. It sounds like month to month continued to improve.
非常感謝。我的問題其實是想了解去年客戶的需求或迫切程度。2025 年,你帶著一些客戶進入了市場,想快速啟動一些項目,並想盡快開始一些研究。第四季度您的需求確實非常強勁。聽起來每個月情況都在持續好轉。
Just interested in any color you can provide about how that has continued into the early part of 26, knowing that. You often remind us that it's not linear and January sometimes get gets off to a slow start, but just kind of comparisons to maybe this time last year and continuation out of the fourth quarter would be great. Thank you.
我只是對你能提供的任何關於這種情況如何延續到 26 年初的資訊感興趣,因為我知道這一點。您經常提醒我們,情況並非線性發展,一月份有時會開局緩慢,但如果能與去年同期進行比較,並延續到第四季度,那就太好了。謝謝。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
So I, I'll start. Maybe Birgit wants to, would want to elaborate. Demand is improving, from a whole host of factors. So, significant inflows of cash into the biotech coffers, pharma companies sort of finishing some of their bloodletting and shrinking down their infrastructures, and just tariff stuff being sort of.
那我就先來吧。或許比爾吉特想詳細說。需求正在改善,這得益於許多因素。因此,大量資金流入生技公司,製藥公司正逐步精簡基礎設施,而關稅方面也出現了一些變化。
Over and whatever pricing situations going on between Washington and the pharma companies we think that that's sort of passed them so demand seems to be improving. We as I said a moment ago, we liked the backlog situation. You'll recall, Dave, two or three years ago the backlog got to about 18 months and we loved it until we loved it till we hated it. It was just way too long and.
至於華盛頓和製藥公司之間可能存在的定價問題,我們認為這些問題已經過去,因此需求似乎正在改善。正如我剛才所說,我們喜歡目前的積壓工作情況。戴夫,你還記得嗎?兩三年前,積壓的工作量達到了大約 18 個月,我們當時很喜歡這種感覺,直到我們開始討厭它。時間太長了。
Clients got to the point of canceling studies, because they just booked slots without a study. So, last couple of years we've seen a lot of post IND work. We'll always have both pre and post. We we're seeing more sort of general talks now which is earlier than the post stuff, so that's good. We're moving towards a greater balance, so that would indicate clients are anxious to start their studies.
客戶甚至到了取消課程的地步,因為他們只是預訂了課程時間,卻沒有進行任何課程。所以,在過去幾年裡,我們看到了很多IND之後的工作。我們總會有事前和事後兩個階段。我們現在看到更多一些一般性的談話,這比事後討論要早,所以這是好事。我們正朝著更平衡的方向發展,這表明客戶們渴望開始他們的學習。
And we want to do that earlier, which obviously is a good thing for us. And while we do get some late stage work, sometimes we don't do the early stage work that's typically we like, we like both and get both. So if we get the early work and the drug is progressing nicely, we'll typically get the post IND work as well. So, sort of a balanced demand quotient right now. Birgit wants to add to that.
我們希望儘早做到這一點,這顯然對我們來說是件好事。雖然我們也會接到一些後期階段的工作,但有時我們卻無法接到通常喜歡的早期階段的工作,我們兩者都喜歡,也都能接到。所以如果我們獲得了早期研究成果,藥物研發進展順利,我們通常也會獲得IND申請後的研究成果。所以,目前需求商處於相對平衡的狀態。比爾吉特想補充一些內容。
Birgit Girshick - Executive Vice President and Chief Operating Officer
Birgit Girshick - Executive Vice President and Chief Operating Officer
Yes. Happy to. Hi, Dave. So maybe just to add that the environment feels a lot more stable than last year. So discussions with Global Biopharma is all about how they can increase the number of candidates, for in the upcoming year and upcoming years. So they're ready, they're definitely ready back to work. They have their programs lined up. From a, biotech mid, small and mid-size biotech, a lot more positivity, in the marketplace that we're hearing about. Certainly, there's still some uncertainty in pockets. Certainly, we're happy about our netbook to bill of above one in Q4. And, so we, we're hoping that the main trends will continue and get us back to, growth in the second half of the year, so.
是的。樂意之至。嗨,戴夫。所以,或許還要補充一點,目前的環境感覺比去年穩定得多。因此,與 Global Biopharma 的討論都圍繞著他們如何增加未來一年和未來幾年的候選藥物數量。所以他們準備好了,他們絕對準備好回去工作了。他們已經安排好了計劃。從生物技術中型、小型和中型生物技術公司的角度來看,我們聽到的市場消息大多是正面的。當然,某些地區仍存在一些不確定性。當然,我們對第四季上網本銷售超過 1 台感到滿意。所以,我們希望主要趨勢能夠持續下去,並在今年下半年恢復成長。
David Windley - Equity Analyst
David Windley - Equity Analyst
Great, if I could follow-up real quickly relative to that better environment, continuing improvement, the book to bill that you just posted in the fourth quarter, your comments about achieving the higher end of your revenue guidance range requires a 1.0 book-to-bill again with the caveat that things aren't linear, but that strikes me as a relatively conservative bar compared to what you just did. Perhaps add some perspective to that, please.
太好了,如果可以的話,我想快速跟進一下,關於更好的環境、持續的改進、您剛剛公佈的第四季度訂單出貨比,您提到要達到收入預期範圍的上限,需要再次達到 1.0 的訂單出貨比,但需要注意的是,事情並非線性發展,不過與您剛剛取得的成績相比,這在我看來是一個相對保守的標準。請您補充一些其他方面的觀點。
Birgit Girshick - Executive Vice President and Chief Operating Officer
Birgit Girshick - Executive Vice President and Chief Operating Officer
Yeah, I'm happy to start and then just I mean, yeah, so, as you outlined, we need a, book to bill above one and it's not going to be linear, so the quarters are not all going to be above one most likely, and the reason for, our outlook and, looking at age two for growth on the top end. It's really that there's other factors in there.
是的,我很樂意開始。我的意思是,正如您所概述的,我們需要訂單出貨比高於 1,但這不會是線性增長,所以很可能每個季度都不會高於 1。我們之所以這樣預測,是因為我們正在展望未來,並著眼於高端市場成長的第二個階段。實際上,這裡面還有其他因素。
Start time, so bookings are still one to two quarters out before they can actually start, the conversion of the backlog, the timing for that. And just, then, overall, the, study starts from the book, when we're getting the booking to when we actually can start starting and get it done in there. So, just a lot of different factors that are playing into it. But certainly very positive of those trends, continuing.
開始時間,所以預訂還需要一到兩個季度才能真正開始,積壓訂單的轉化,以及轉換的時間表。總的來說,研究是從書本開始的,從我們開始預訂到真正開始並完成它。所以,有很多不同的因素在起作用。但可以肯定的是,我對這些趨勢的持續發展持非常積極的態度。
David Windley - Equity Analyst
David Windley - Equity Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Thank you. Charles Rhyee, TD Cowen.
謝謝。Charles Rhyee,TD Cowen。
Charles Rhyee - Analyst
Charles Rhyee - Analyst
Yeah, thanks for taking the question. Hey, maybe, well, first of all, Jim and Berger, congratulations to the both of you and Jim. Good luck for, the future, and Berger looking forward to meeting you soon. Maybe if I could just ask about sort of the guide for, coming up here understanding the headwinds that you kind of laid out, particularly for the first quarter and when you talk about sort of this material improvement in margins going forward, I mean, it sounds like you're saying that. Obviously some of these kind of reverse as we exit the quarter. Can you kind of lay out which one's fully exit or which ones might carry through or or should we really kind of assume sort of a big step function in margins into the second quarter and then it kind of flattens out there? Or should we be modeling more of a gradual ramp back in margins as we, think through the course of the year.
好的,謝謝你回答這個問題。嘿,或許,首先,吉姆和伯傑,恭喜你們兩個和吉姆。祝你未來一切順利,伯傑期待很快與你見面。也許我可以問一下關於如何理解您之前提到的不利因素的指導原則,特別是針對第一季度的不利因素,以及您談到未來利潤率的實質改善,我的意思是,聽起來您是這麼說的。顯然,隨著季度末的臨近,其中一些情況會發生逆轉。你能大致說明一下哪些公司會完全退出市場,哪些公司可能會繼續營運下去,或者我們是否應該假設第二季利潤率會大幅躍升,然後趨於平穩?或者,我們應該設想利潤率在一年內逐步回升?
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
Mike, why don't you take that? Yeah, hey.
麥克,你為什麼不拿走呢?是啊,嘿。
Michael Knell - Interim Chief Financial Officer
Michael Knell - Interim Chief Financial Officer
Charles, thank you. So when I think about the sequential improvement in the operating margin is really three main drivers of that. The first one we're going to get continued benefit from the cost savings and our efficiency initiatives as we go throughout the year. And then second one is the lower sourcing, related to the KF acquisition.
查爾斯,謝謝你。所以,我認為營業利益率的持續改善主要有三個驅動因素。首先,我們將全年持續受益於成本節約和效率提升措施。其次是較低的採購量,與 KF 收購有關。
So we're going to, we solidified that supply chain and I think, the headwind that we're seeing in Q1 of having more bookings and have to go out to the open market to purchase those is really dissipated by the fact that we have such a majority owned portion of that supply chain.
所以,我們已經鞏固了供應鏈,我認為,我們在第一季遇到的不利因素,例如訂單增多,不得不到公開市場採購,由於我們擁有供應鏈的大部分所有權,這些不利因素實際上已經消除。
So that'll go away, and then our cautious optimism that the demand's going to continue to improve, over the course of the year. So that strong book to bill, that you saw in Q4, that's going to materialize into revenue, as we progress, into 2026.
所以這種情況會消失,然後我們謹慎樂觀地認為,需求將在今年內持續改善。所以,您在第四季看到的強勁訂單出貨率,隨著我們推進到 2026 年,將會轉化為實際收入。
Charles Rhyee - Analyst
Charles Rhyee - Analyst
And just to and maybe just to follow-up then, does that the extra sourcing cost where you kind of had because of the greater than normal number of study starts, so you have to kind of go outside more so more demand than the slide that you had is it that you expect that kind of level of sourcing required and that KF then offsets that, or is it that, you expect sort of that kind of bolus of study starts to maybe subside and so you don't need to tap the market outside of your existing supply? Thanks.
那麼,為了跟進一下,由於研究啟動數量比正常情況要多,導致額外的採購成本,也就是因為需求比預期要大,所以需要更多地從外部採購,您預計需要這種程度的採購,而KF可以抵消這部分成本嗎?或者您預計這種研究啟動數量的激增可能會消退,因此您不需要從現有供應之外的市場採購?謝謝。
Michael Knell - Interim Chief Financial Officer
Michael Knell - Interim Chief Financial Officer
Yeah, it's like it's a little bit of both, right? You're going to get the impact of the KF in the second half of the year. We've had obviously more time to plan for the increased demand, in the second quarter. The other pieces of Q1, right, are the NHP timing. So that is just a function of when the models are ready to be used and shipped and when the demand is, and that's simply timing in Q1.
是啊,感覺兩者兼而有之,對吧?你將在今年下半年感受到KF的影響。顯然,我們有更多的時間來規劃應對第二季度不斷增長的需求。Q1 的其他部分,沒錯,就是 NHP 的時機。所以,這僅僅取決於模型何時準備好投入使用和發貨,以及何時有需求,而這只是第一季的時間表。
And then, of course, in Q1 you've got the stock comp, right? That's just the accounting rules of how you have to. Accelerate the expense over the service period. So we, with the retirement and the succession, we're going to get a pretty heavy, headwind in Q1 on the stock comp that, that's improved throughout the year too. It's not a headwind on, the year.
當然,第一季還有股票價格競爭,對吧?那是會計準則,必須遵守。在服務期內加速支出。因此,隨著退休和繼任,我們在第一季將面臨相當大的股票薪資阻力,儘管這種情況在今年稍早有所改善。今年並沒有什麼不利因素。
Charles Rhyee - Analyst
Charles Rhyee - Analyst
All right, great. I really appreciate the comments. Thank you guys.
好的,太好了。非常感謝大家的評論。謝謝大家。
Operator
Operator
Yeah.
是的。
Thank you. Elizabeth Anderson, Evercore.
謝謝。伊麗莎白·安德森,Evercore。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Hi guys. Good morning and thanks for the question. Congrats, Jim, Birgit, it's, on your new roles. I think that's, it will be a good transition. Maybe just digging into the, outlook here. Can you talk about the demand environment in China right now, particularly in regards to RMS, but anything else you're seeing there. And then anything you would, chalk up the improvement in biologics to, that you mentioned for the fourth quarter.
嗨,大家好。早安,謝謝你的提問。恭喜吉姆、比爾吉特,恭喜你們履新。我認為這將是一個好的過渡。或許應該深入探討一下這裡的前景。您能否談談目前中國的需求環境,特別是RMS方面,以及您觀察到的其他方面?然後,你可以把第四季生物製劑的進步歸功於你提到的部分。
Thank you.
謝謝。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
So, our China business continues to perform well, it's all RMS as and it's an important market for us and, we feel that we've elevated the craft of producing really high-quality pristine. Animals and sort of taught the industry, the benefit of utilizing those in terms of the quality of the work that they do, and China is becoming a more sophisticated, innovative.
所以,我們在中國的業務繼續表現良好,一切都很順利,而且中國對我們來說是一個重要的市場,我們覺得我們已經提升了生產真正高品質純淨產品的工藝。動物們教會了該行業如何利用動物來提高工作質量,而中國正變得越來越成熟、越來越具有創新精神。
Local, for sure, a lot of investment by the government, and, you didn't specifically ask this, but I'm just going to throw this in there that, we're looking closely at China, with regard to what additionally we can do there besides RMS given that it's a big, obviously a big patient population, drugs developed in China have to be tested in China and so.
本地肯定投入了大量資金,政府也投入了大量資金。雖然你沒有特別問到這一點,但我還是要補充一點:我們正在密切關注中國,除了RMS之外,我們還能在那裡做些什麼。因為中國顯然擁有龐大的病患群體,在中國研發的藥物必須在中國進行測試等等。
Except for the research model part which we're thrilled with, we're not accessing any of the service revenue associated with that, so China may become a bigger part of our portfolio going forward. Biologics was, it's been a really good business for us for a long time. It had sort of a complicated '25, due to some lower sample volumes from a couple of large clients due principally to project delays and regulatory challenges, but that this has returned to growth in the in the fourth quarter of '25 due to higher demand principally from Europe and we would expect.
除了我們非常滿意的研究模型部分之外,我們無法獲得與之相關的任何服務收入,因此中國未來可能會成為我們投資組合中更大的一部分。生物製劑一直是我們非常好的業務,而且已經持續很久了。2025 年的情況比較複雜,主要是由於幾個大客戶的樣品量減少,這主要是由於專案延誤和監管方面的挑戰,但這種情況在 2025 年第四季度已經恢復增長,這主要是由於歐洲等地的需求增加,我們預計未來幾年也會如此。
Some of those clients specific challenges, those are behind us as we move into '26. So an important business, obviously only testing large molecules, at least half of the drugs that are approved are large molecules going forward.
隨著我們邁入 2026 年,一些客戶特有的挑戰已經過去了。所以,這顯然是一項重要的業務,只測試大分子,未來至少有一半核准的藥物都是大分子。
So, a business that we think we have a strong position in, it has had years of very nice growth and escalating op operating margins. So it's beginning to sort of come back. It was a business that was very much benefited by COVID, and things sort of slowed down and now we're beginning to see them ramp up again.
因此,我們認為我們在這個行業擁有強大的地位,該行業多年來一直保持著非常好的成長,營業利潤率也在不斷提高。所以它正在慢慢恢復。這家企業曾因新冠疫情而受益匪淺,後來業務有所放緩,現在我們開始看到它又開始加速發展了。
Operator
Operator
Thank you. Michael Ryskin, Bank of America.
謝謝。邁克爾·里斯金,美國銀行。
Michael Ryskin - Analyst
Michael Ryskin - Analyst
Great, thanks for taking the question. I'll just do one given the time, just following up on your earlier comments on. DSA demand environment what you saw in 4Q expectations for the coming year. I kind of want to go back to 2025. You had a pretty strong start to the year, then a little bit of a lull over the summer months in terms of demand, and then a pick up again in the recent months. Just wondering, that volatility, that uncertainty, those fluctuations, would you attribute that more to the macro environment, the geopolitical environment, rates environment? I'm, what I'm getting at is.
太好了,謝謝你回答這個問題。鑑於時間允許,我就做一件,只是跟進你之前的評論。DSA需求環境,您在第四季看到的,以及對來年的預期。我有點想回到2025年。今年開局相當強勁,夏季幾個月需求略有下降,但最近幾個月又有所回升。我只是想知道,這種波動性、不確定性和波動,您認為更多地歸因於宏觀環境、地緣政治環境還是利率環境?我的意思是,
What gives you confidence that we wouldn't see something similar this year or that, 4Q, the strength you saw in 4Q25 isn't a little bit of a red herring and we take a step back, just what makes you think that last year was an outlier in that regard? Thanks.
是什麼讓您確信今年不會出現類似情況,或者說,您在2025年第四季看到的強勁表現並非只是暫時的干擾因素?讓我們回顧一下,究竟是什麼讓您認為去年的情況在這方面是個例外?謝謝。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
I mean, the big impact from us was overall soft demand from, our client base, both large and small companies, both new and old companies. Who were really working on the biotech companies were really concerned about access to capital and whether they had enough funding to work on a whole range of drugs. So we're we're, it's quite clear to us that they paused some drugs before they filed their IDs. So we think they're going to get back to that.
我的意思是,我們造成的最大影響是客戶群(包括大公司和小公司、新公司和老公司)的整體需求疲軟。真正為生技公司工作的人非常關心資金的獲取,以及他們是否有足夠的資金來研發各種藥物。所以,我們很清楚,他們在提交身分證之前暫停了某些毒品的使用。所以我們認為他們會回到那個狀態。
And big pharma is facing another patent cliff which you know we saw this, I don't know, 12,13,14 years ago. They begin to pull back on their cost structure. By the way, one of the things we do is help them alleviate or reduce some of their internal costs because we can, the work that we do in safety assessment is as fast if not faster, a lower price point, and, probably in most cases better science.
大型製藥公司正面臨另一次專利懸崖,你知道,我們大概在 12、13、14 年前就見過這種情況了。他們開始縮減成本結構。順便說一下,我們所做的一件事就是幫助他們減輕或減少一些內部成本,因為我們能夠做到這一點,我們在安全評估方面所做的工作速度即使不是更快,也至少與他們一樣快,價格更低,而且在大多數情況下,科學性可能更好。
So, we're trying, we're being cautious, we said that we're trying not to overcall it because it's not linear, and one quarter doesn't necessarily portend the next, but what is beginning to change is, the massive amount of funding that went into the biotech companies, $28 billion in the fourth quarter was quite significant. And so if that continues, January was a good month as well, but if that continues, that should generate, incremental demand going forward.
所以,我們正在努力,我們很謹慎,我們說過我們盡量不妄下斷言,因為它並非線性發展,一個季度的情況並不一定預示著下一個季度的情況,但正在發生變化的是,大量資金湧入生物技術公司,第四季度高達 280 億美元,這相當可觀。因此,如果這種情況持續下去,1 月也是一個不錯的月份,但如果這種情況持續下去,應該會在未來產生增量需求。
There's usually a lag time between cash coming in and then, booking studies. So, we're going to see that in the second quarter, but more pronounced in the back half of the year. The fact that book to bill was above 1 time and much and much higher than that in December.
通常情況下,資金到帳和預約研究之間會有一段時間的延遲。所以,我們在第二季會看到這種情況,但在下半年會更加明顯。12 月的帳面出貨比超過 1 倍,而且比這個數字還要高得多。
Is obviously a very important point and that's also going to benefit the second quarter and the second half of the year, so we're trying not to overcall it, but what we have been looking for and what we've been hearing from our clients just in terms of funding and access to continued funding, is beginning to happen, and since the preponderance of our revenue, we have really big market shares in Big Pharma, but the preponderance of our revenue and the growth rate for the last decade has been principally from hundreds and hundreds and hundreds of biotech companies, none of whom Have the internal capacity to do anything that we do for them, so they must outsource. They don't have to outsource to Charles River, but most of them do. So they must outsource and so.
這顯然是一個非常重要的方面,而且對第二季和下半年也有好處,所以我們盡量不誇大其詞。但我們一直在尋找的,以及我們從客戶那裡聽到的關於資金和持續獲得資金的訴求,正在開始實現。雖然我們的大部分收入來自大型製藥公司,我們在大型製藥公司擁有非常大的市場份額,但過去十年我們的大部分收入和增長率主要來自數百家生物技術公司,這些公司沒有內部能力為他們做我們所做的任何事情,所以他們必須外包。他們不必將業務外包給查爾斯河公司,但大多數公司都這麼做了。所以他們必須外包等等。
Just given the, number, and diversity of new modalities to treat or cure diseases, these folks have to get back to work and, that should generate additional volume for us and, we're obviously comfortable with the guidance we've just given today.
鑑於治療或治癒疾病的新方法的數量和種類如此之多,這些人必須重返工作崗位,這應該會給我們帶來額外的業務量,而且我們顯然對今天給出的指導意見感到滿意。
And again, we're being, I think, cautiously optimistic is really a good way to put it.
再次強調,我認為,謹慎樂觀是個非常貼切的說法。
Michael Ryskin - Analyst
Michael Ryskin - Analyst
Appreciate all that, Jim.
吉姆,非常感謝你。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
Thank you wrapping up.
謝謝總結。
Operator
Operator
Thank you. Casey Woodring with JP Morgan.
謝謝。Casey Woodring,摩根大通員工。
Casey Woodring - Analyst
Casey Woodring - Analyst
Great, thank you for taking my questions and yeah, Jim, again, congratulations on retirement and Burge looking forward to working with you in the in the new role yeah maybe just sticking to one on the capital deployment comments so you talked about maintaining dry powder for M&A. How should we think about that, in relation to some of the comments you made about the opportunity in China and then how do we balance that versus repost this year, you mentioned the violent share price movement of late. And then also curious if you're looking at other deals like KF that could potentially alleviate some NHP sourcing costs, some of the headwinds that you, you've seen, in DSA to start the year.
太好了,謝謝你回答我的問題。還有,吉姆,再次恭喜你退休,伯格期待在新崗位上與你共事。是的,也許我們只討論一下資本部署方面的問題,你剛才談到了為併購保持充足的資金。我們該如何看待這一點?結合您先前對中國市場機會的一些評論,以及我們如何平衡這項機會與今年的股價波動?您提到了近期股價的劇烈波動。另外,我還想知道您是否在尋找像 KF 這樣的其他交易,這些交易可能會緩解一些 NHP 採購成本,以及您在 DSA 今年年初遇到的一些不利因素。
Thank you.
謝謝。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
So our NHP sourcing volume is in really good shape now given that Nova rim and the deal that we just did with KF. So, it, it's highly unlikely that, we'll need to, source, anything further or buy anything further, we, we're, we already have plans to increase the Mauritian operation and if the demand continues we can increase both of them so we feel that just in terms of.
鑑於 Nova rim 和我們剛剛與 KF 達成的交易,我們的 NHP 採購量目前狀況非常好。所以,我們不太可能需要進一步採購或購買任何東西,我們已經有計劃擴大毛里求斯的業務,如果需求持續,我們可以同時擴大這兩個業務,所以我們覺得就目前而言,情況就是這樣。
Quality of the NHPs, price point, just the quality of the farms that they're bred on, we're really comfortable in that. Capital deployment for us is pretty straightforward. We like to keep our leverage below 3 turns and we've been able to buy many businesses over the years and, we lever up to high 2s, occasionally over 3 and. We usually delever within 12 months, so we feel really good about that. Our balance sheet is in really strong shape, pre these deals, and, even after these deals, our leverage is, just, in the high 2s, and we'll continue to work it down. So we have a committee of the board that I sit on and, we TRY to object, not TRY to, we objectively look at, uses of capital every single quarter, in tandem with our board meetings and. Paying down debt, share buybacks, M&A is always on the table, so we're certainly continue to look at M&A in some of the areas that we've talked about, bio bioanalysis is probably top of our list, and as I said, we're beginning to look closely at China.
我們對自然人畜的品質、價格以及它們所飼養的農場的品質都非常滿意。對我們來說,資金部署非常簡單直接。我們喜歡將槓桿率保持在 3 倍以下,多年來我們收購了許多企業,我們的槓桿率最高可達 2 倍以上,偶爾甚至超過 3 倍。我們通常會在 12 個月內降低槓桿率,所以我們對此感到非常滿意。在這些交易之前,我們的資產負債表狀況非常穩健;即使在這些交易之後,我們的槓桿率也只有 2% 以上,我們將繼續努力降低槓桿率。所以我們有一個董事會委員會,我也是其中一員。我們努力提出反對意見,不是“努力”,而是客觀地審視每個季度的資金使用情況,這與我們的董事會會議同步進行。償還債務、股票回購、併購始終是我們考慮的選項,因此我們肯定會繼續關注我們討論過的一些領域的併購,生物分析可能是我們最關注的領域,正如我所說,我們開始密切關注中國市場。
Way too early to to predict that buying back stock is totally dependent on other what else do we have a better use and what does the share price look like, and we continue to pay down our debts. So, I think we have a lot of flexibility right now. We just had a board meeting, last week where we talked about all these things, have another one in May, and, we'll continue to stay on it, but. There's definitely some areas that we'd like to continue to fill in the portfolio, from M&A, and every once in a while we may, come across one of our businesses where we don't think it has long-term, value for us, and so we would take a look at, divesting those as well.
現在預測股票回購是否完全取決於其他因素,例如我們是否有更好的用途、股價走勢如何,以及我們是否繼續償還債務,都為時過早。所以,我認為我們現在有很大的靈活性。我們上週剛開過一次董事會,討論了所有這些事情,五月還有一次,我們會繼續關注此事,但是。我們肯定希望繼續透過併購來完善投資組合中的某些領域,而且我們偶爾也會遇到一些我們認為沒有長期價值的業務,所以我們會考慮剝離這些業務。
Casey Woodring - Analyst
Casey Woodring - Analyst
Great thank you.
非常感謝。
Sure.
當然。
Operator
Operator
Thank you. Justin Bowers, Deutsche Bank.
謝謝。賈斯汀·鮑爾斯,德意志銀行。
Justin Bowers - Analyst
Justin Bowers - Analyst
Hi, good morning, everyone, and congratulations Jim and Birgit. So I want to sort of follow-up on MOC's earlier question and hopefully you can educate us a little bit more on dams.
大家好,早安,恭喜吉姆和比爾吉特。所以我想就 MOC 之前提出的問題做個後續探討,希望您能再給我們普及一些關於水壩的知識。
If I recall, it's about 20% of DSA revenue. Can you provide us with a sense of how the client base is using these methods? And the gist of the question is, are these technologies being platformed by a high end full of clients or more concentrated, or? Is adoption and uptake fairly diverse across a large number of clients that are using this tech technologies perhaps to perhaps to validate existing in vivo methods.
如果我沒記錯的話,這大約佔DSA收入的20%。您能否介紹一下客戶群是如何使用這些方法的?問題的重點是,這些技術是由眾多高階客戶組成的平台,還是更集中化的平台,或是其他什麼情況?眾多客戶採用和接受這種技術的情況是否相當多元?他們或許是為了驗證現有的體內方法。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
So we're seeing, we, we're seeing thes across, a big swath of our client base, we would say that, Big Pharma has been looking at utilizing in vitro or non-animal technologies sort of forever. Lots of that's proprietary to each company, and some of it's just sort of standard stuff. It's definitely more pronounced in discovery as we, we've been saying now, as we've been talking about this most of the last year.
所以我們看到,在我們龐大的客戶群中,可以說,大型製藥公司一直以來都在尋求利用體外或非動物技術。其中很多都是各公司的專有技術,有些則是標準技術。在勘探領域,這種現象肯定更為明顯,正如我們過去一年來一直在談論的那樣。
And everybody hopes that some of these technologies, albeit somewhat anecdotal, help the process of accelerating our clients getting to a lead compound and spending less time on drugs that have a low probability of getting into the clinic and more time on drugs that have a higher probability. Of course we get paid either way whether the drug advances to the clinic or not, so we're there to help them, and if the technology helps us make a determination with and for the client, we're certainly happy, to do that, as we, as we've said before, there's, our path quest deal that, we just talked about on this call, is a non-animal technology, next generation sequencing that's, that literally is replacing some of the animal-based work that we do in our biologics business and that's a really good hands that you know we're happy to provide that service and our clients are demanding it and it gives better answers faster. We also have another business we talked about in the call retrogenics where we're looking at off-target effects of drugs, which is really important, so.
每個人都希望這些技術(儘管有些是軼事性的)能夠幫助我們的客戶更快地找到先導化合物,減少在進入臨床試驗概率較低的藥物上花費的時間,而將更多的時間花在進入臨床試驗概率較高的藥物上。當然,無論藥物是否進入臨床試驗階段,我們都會獲得報酬,所以我們會盡力幫助他們。如果這項技術能夠幫助我們與客戶共同做出決定,我們當然非常樂意這樣做。正如我們之前所說,我們與PathQuest的合作項目,也就是我們剛才在電話會議上提到的,是一項非動物實驗技術,屬於下一代定序技術,它實際上正在取代我們生物製劑業務中一些基於動物的實驗工作。這項技術非常可靠,我們很樂意提供這項服務,我們的客戶也需要這項服務,因為它能更快地給出更好的答案。我們在電話會議中也談到了另一項業務——逆轉錄,我們正在研究藥物的脫靶效應,這非常重要。
There are some naams now that are beneficial and utilizable. There are some that are sort of, hopeful, but still early days, and we believe we're only going to see it in safety in a sort of narrow monoclonal antibody swath that the FDA has talked about and too much of a safety risk to be focusing on these as replacements, but likely to be augmentative to some of the wet lab work, particularly in the early phases. So we'll continue to license in technologies and periodically buy something that we think is really beneficial for our clients and we generate a decent revenue and margin.
現在有一些名字是有益的,也是可以利用的。有些方面令人充滿希望,但仍處於早期階段。我們認為,我們只能在FDA所討論的某種狹窄的單株抗體範圍內看到安全性,而且安全風險太大,不宜將其作為替代品,但可能會對一些濕實驗室工作起到補充作用,尤其是在早期階段。因此,我們將繼續引進技術,並定期購買我們認為對客戶真正有益且能帶來可觀收入和利潤的技術。
We'll work with our clients in validation. But this is a long-term marathon and not something that's going to be done quickly or overnight.
我們將與客戶合作進行驗證。但這卻是一場持久戰,不是一朝一夕就能完成的。
Justin Bowers - Analyst
Justin Bowers - Analyst
Thank you, and if I may with just a quick follow-up since this is so topical, I was speaking with, top 10 pharma. Last week and we're talking about AI and how that would, potentially impact, early stage, and they said, well, maybe we could see a scenario where we start with, 20,000 targets instead of 10 at the top of the funnel. Can you help us understand how that would sort of flow through, your business? And if that would be accretive, diluted, neutral.
謝謝,如果可以的話,我想快速跟進一下,因為這個話題非常熱門,我之前和排名前十的製藥公司談過。上週我們討論了人工智慧及其可能對早期階段產生的影響,他們說,或許我們會看到這樣一種情況:在銷售漏斗的頂端,我們一開始就有 20,000 個目標,而不是 10 個。您能幫我們了解一下這在您的業務中會如何運作嗎?如果結果是累積性的、稀釋性的、中性的。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
Yeah, I, yeah, more targets would be, I, if you can screen through more targets, at the same pace or faster, that's obviously really beneficial for our clients and should be beneficial for us as well, as I said, if they can go just using your numbers, if they can screen through 20,000.
是的,是的,更多的目標意味著,如果你能以相同的速度或更快的速度篩選出更多的目標,這顯然對我們的客戶非常有利,對我們也應該有利,正如我所說,如果他們能夠僅使用你的數據,如果他們能夠篩選出 20,000 個目標。
Potential drugs that hit the target, and then they can focus on the ones that have the highest probability of actually working and being tolerated by patients who get into the clinic, that should generate incremental work for us and it should also have a higher hit rate for the drug companies. It's sort of Shocking. I would say that all of the US pharmaceutical and biotech companies in the aggregate, only, we only have between 40 and 50 new drugs a year, right?
潛在的藥物如果能夠擊中目標,他們就可以集中精力研究那些最有可能真正有效且患者能夠耐受的藥物,這應該會給我們帶來更多的工作,同時也應該會給製藥公司帶來更高的成功率。這有點令人震驚。我想說,僅就美國所有製藥和生技公司而言,我們每年也只有 40 到 50 種新藥,對吧?
So if that could be 100 or 200 or 500, that obviously would be better for society, that obviously would be better for human health, it definitely would be better for Charles River, it would be better for our clients. So, the extent to which AI can get its arms, speaking to it as if it's a person get its arms around more data earlier, and have a bigger funnel, that I think that would be beneficial for all of us.
所以,如果能達到 100、200 或 500,那顯然對社會更有利,對人類健康更有利,對查爾斯河實驗室肯定更有利,對我們的客戶也更有利。所以,人工智慧如果能像人一樣與它對話,更早掌握更多數據,並擁有更大的資訊管道,我認為這對我們所有人都有好處。
Thank you.
謝謝。
Operator
Operator
Thank you. Patrick Donnelly, Citi.
謝謝。派崔克唐納利,花旗銀行。
Patrick Donnelly - Analyst
Patrick Donnelly - Analyst
Hey guys, thanks for the questions. Maybe this one obviously covered a lot of ground here. Maybe the vestiture process. Jim, can you just update us where we are there? It sounds like negotiations still going with the buyers. What hurdles are left? It sounds like it'll be done by mid-year when that capital comes in the door. Is that deployed relatively quickly? Just a quick update on that process would be helpful.
大家好,感謝你們的提問。或許這篇文章涵蓋的內容確實很廣泛。或許是所有權變更程序。吉姆,你能告訴我們一下我們那邊的情況嗎?聽起來雙方仍在與買家進行談判。還有哪些障礙需要克服?聽起來,等到年中資金到位後,這個計畫就能完成了。部署速度相對較快嗎?簡單報告一下進展就好。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
I mean the process is ongoing, we have sophisticated investment banks working on these divestitures. We have interested parties. The comment that we made, in our last quarter call, still seems reasonable that, we hope to close these divestures sometime in the first half of this year and.
我的意思是,這個過程仍在進行中,我們有經驗豐富的投資銀行參與這些資產剝離工作。我們已經找到了感興趣的各方。我們在上一季電話會議上發表的評論仍然合理,即我們希望在今年上半年完成這些資產剝離。
And perhaps and hopefully we can sign something sooner but it's it's it's difficult to tell. I mean the the these deals aren't signed until they're signed and they're not closed till they're done so we're very committed to finalizing the process we think we have some interested folks and should.
或許,也希望,我們能盡快簽署協議,但現在很難說。我的意思是,這些交易只有真正簽署才算完成,只有全部完成才算最終敲定,所以我們非常致力於完成這個過程,我們認為已經有一些感興趣的人,而且應該如此。
It should be a good result in terms of what we do with the proceeds again it's sort of what we do with any of our proceeds what we do with any of our cash as we look at M&A debt repayment, share purchases, all of the above, or or just one of the above, and it's always contextual. It depends on what's going on with the market demand, what the rest of our M&A portfolio looks like, what the share price looks like, and. We do that, I think, very well, very objectively, very thoughtfully every quarter. We don't have any sort of preordained feelings about that.
就我們如何處理收益而言,這應該是一個好結果。這和我們如何處理任何收益、如何處理任何現金都差不多,我們會考慮併購債務償還、股票購買、以上所有或以上其中一項,而且這總是要視情況而定的。這取決於市場需求的狀況、我們併購組合的其他情況、股價的走勢等等。我認為,我們每季都做得非常好,非常客觀,非常周全。我們對此沒有任何預設的看法。
So, when we bring these, deals to closure, we'll see what the world looks like at that time in terms of what we do with the, assets.
所以,當我們完成這些交易時,我們會看看屆時世界狀況如何,以及我們將如何處理這些資產。
Patrick Donnelly - Analyst
Patrick Donnelly - Analyst
Okay, and then maybe one last quick one on the NHPs, obviously KF is a nice impact this year. As you look out, beyond this year, is it almost a compounding effect on the NHP side where, you benefit more on the savings as you insource more from in '27 from NovoPrim and KF both being on Board there.
好的,最後再快速提一下NHP(國家隊球員),顯然KF(塞爾提克)今年的表現非常出色。展望未來,從今年開始,NHP 方面幾乎會產生複利效應,隨著 NovoPrim 和 KF 在 2027 年加入,您將從內部採購更多產品,從而獲得更多節省。
James Foster - Chair, President, Chief Executive Officer
James Foster - Chair, President, Chief Executive Officer
When I take that, Mike?
我什麼時候拿走它,麥克?
Michael Knell - Interim Chief Financial Officer
Michael Knell - Interim Chief Financial Officer
Yeah, absolutely. So yeah, we said, that there would be a $0.25 benefit this year and then even next year would be even further, we think that there's approximately $0.60 accretion from KF as we go into 2027.
是的,絕對的。所以,我們說過,今年會有 0.25 美元的收益,明年還會更多,我們認為到 2027 年,KF 將帶來約 0.60 美元的收益。
Operator
Operator
Thank you. We have no further questions in queue. I will now turn the conference back to Todd Spencer for closing remarks.
謝謝。我們沒有其他問題需要提問了。現在我將把會議交還給托德·斯賓塞,請他作閉幕致詞。
Todd Spencer - Corporate Vice President, Investor Relations
Todd Spencer - Corporate Vice President, Investor Relations
Great, thank you for joining us on the conference call this morning. We look forward to seeing you at upcoming investor conferences in March. This concludes the call. Thanks again.
太好了,感謝您今天上午參加我們的電話會議。我們期待在三月即將舉行的投資者會議上見到您。通話到此結束。再次感謝。
Operator
Operator
Thank you. That does conclude today's Charles River Laboratories fourth quarter and full year 2025 earnings call. Thank you for your participation and you may now disconnect.
謝謝。查爾斯河實驗室2025年第四季及全年財報電話會議到此結束。感謝您的參與,您現在可以斷開連接了。